Methods and compositions for gene transfer across vascular structures

By performing specific amino acid modification and insertion of AAV capsid proteins, the improved AAV capsid protein is generated, which solves the problem of AAV vectors passing through the blood-brain barrier and vascular structure, and achieves efficient selective delivery and reduction of neuronal cells. Transduction of non-target organs.

CN118978574APending Publication Date: 2024-11-19THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410828011.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-02-15
Filing Date
2018-02-15
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing adeno-associated virus (AAV) vectors are difficult to effectively pass through vascular structures, especially the blood-brain barrier, resulting in inefficient gene transfer and inability to selective delivery of neuronal cells.

Method used

By modifying and inserting specific amino acid residues on the AAV capsid protein, AAV capsid protein with improved properties is generated, combining specific amino acid sequence changes, so that viral vectors can pass through the blood-brain barrier and achieve neuronal cells. Selective transduction.

Benefits of technology

The transduction efficiency of AAV vectors in neuronal cells was significantly improved, selective delivery of neuronal cells was achieved, and de-targeting efficiency to the liver, spleen and kidneys was reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978574A_ABST
    Figure CN118978574A_ABST
Patent Text Reader

Abstract

The present disclosure relates to methods and compositions for gene transfer across vascular structures. In particular, the disclosure provides for a modified AAV capsid protein in the amino acid sequence, as well as viral capsids and viral vectors comprising a modified AAV capsid protein. The disclosure also provides methods of intracorporeal administration of the viral vectors and viral capsids of the disclosure to a cell or subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the application with an international application date of February 15, 2018, international application number PCT / US2018 / 018381 entering the Chinese national phase, application number 201880025093.X, and invention name “Methods and compositions for gene transfer across vascular structures”.

[0002] Cross-references

[0003] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 459,286, filed on February 15, 2017, which is incorporated herein by reference in its entirety for all purposes.

[0004] Government Support Statement

[0005] This invention was made with government support under Grant Nos. P01HL112761 and R01HL089221 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0006] Sequence Listing

[0007] The sequence listing associated with this application is provided in text format in lieu of a paper copy and is incorporated into this specification by reference. The name of the text file containing the sequence listing is STRD_004_01WO_SeqListSST25.txt. The text file is 4KB, created on February 14, 2018, and submitted electronically via EFS-Web. Field of the Invention

[0008] The present invention relates to modified capsid proteins from adeno-associated viruses (AAVs) and viral capsids and viral vectors comprising the same. In particular, the present invention relates to modified AAV capsid proteins and capsids comprising the same, which can be incorporated into viral vectors to confer a desired transduction profile on target tissues of interest. Background Art

[0009] New adeno-associated virus (AAV) strains isolated from animal tissues and adenoviral stocks have expanded the set of AAV vectors available for therapeutic gene transfer applications. Comprehensive efforts are currently underway to map the tissue tropism of these AAV isolates in animal models. The ability to direct the homing of AAV vectors to selective organs is useful for gene therapy and other therapeutic applications.

[0010] The present invention addresses the need in the art for nucleic acid delivery vehicles with desirable targeting characteristics. Summary of the invention

[0011] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises modifications at amino acid residues S262, A263, S264, T265, A267, S268 and H272, and a single amino acid residue insertion between residues G266 and A267, (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of AAV1 (SEQ ID NO: 1), or the equivalent amino acid residue in AAV2 (SEQ ID NO: 2), AAV3 (SEQ ID NO: 3), AAV6 (SEQ ID NO: 4), AAV7 (SEQ ID NO: 5), AAV8 (SEQ ID NO: 6), AAV9 (SEQ ID NO: 7), or AAVrh10 (SEQ ID NO: 8). In some embodiments, the AAV capsid protein of the invention can further comprise modifications at amino acid residues Q148, E152, S157, T162, T326, D328, V330, T331, V341, and S345, and a single amino acid residue insertion between residues E152 and P153 (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of SEQ ID NO: 1, or the equivalent amino acid residue in SEQ ID NO: 2, 3, 4, 5, 6, 7, or 8. In further embodiments, the AAV capsid protein of the invention can further comprise modifications at amino acid residues L188, S205, N223, and A224 (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of SEQ ID NO: 1, or the equivalent amino acid residue in SEQ ID NO: 2, 3, 4, 5, 6, 7, or 8.

[0012] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises modifications at amino acid residues S262, A263, S264, T265, and A267 (VP1 numbering), and a single amino acid residue insertion between residues S268 and N269, wherein the amino acid residues are based on the amino acid sequence of AAV1 (SEQ ID NO: 1) or the equivalent amino acid residues in AAV2 (SEQ ID NO: 2), AAV3 (SEQ ID NO: 3), AAV6 (SEQ ID NO: 4), AAV7 (SEQ ID NO: 5), AAV8 (SEQ ID NO: 6), AAV9 (SEQ ID NO: 7), or AAVrh10 (SEQ ID NO: 8). In some embodiments, the capsid protein further comprises a modification at amino acid residue H272. In some embodiments, the AAV capsid protein further comprises modifications at amino acid residues Q148, E152, S157, T162, H272, T326, D328, V330, T331, V341, and S345, and a single amino acid residue insertion between residues E152 and P153. In further embodiments, the AAV capsid protein further comprises modifications at amino acid residues L188, S205, N223, A224, and H272.

[0013] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises a modification resulting in the following amino acid sequence: X at amino acids corresponding to amino acid positions 262 to 265 (VP1 numbering) of a native AAV1 capsid protein (SEQ ID NO: 1); 1 -X 2 -X 3 -X 4 (SEQ ID NO: 35), wherein X 1 is any amino acid except S; 2 is any amino acid except A; 3 is any amino acid except S; 4 It is any amino acid except T.

[0014] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises modifications at amino acid residues S262, A263, S264, T265, A267 and H272, and a single amino acid residue insertion between residues S268 and N269, (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of AAV1 (SEQ ID NO:2) or the equivalent amino acid residue in AAV1 (SEQ ID NO:1), AAV3 (SEQ ID NO:3), AAV6 (SEQ ID NO:4), AAV7 (SEQ ID NO:5), AAV8 (SEQ ID NO:6), AAV9 (SEQ ID NO:7), or AAVrh10 (SEQ ID NO:8).

[0015] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises modifications at amino acid residues S262, Q263, S264, A266, S267 and H271, and an insertion of at least one amino acid residue between residues S261 and S262, (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of AAV2 (SEQ ID NO:2) or the equivalent amino acid residue in AAV1 (SEQ ID NO:1), AAV3 (SEQ ID NO:3), AAV6 (SEQ ID NO:4), AAV7 (SEQ ID NO:5), AAV8 (SEQ ID NO:6), AAV9 (SEQ ID NO:7), or AAVrh10 (SEQ ID NO:8).

[0016] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises modifications at amino acid residues S262, Q263, S264, A266, A267, H271, and a single amino acid residue insertion between residues S261 and S262, wherein the numbering of each residue is based on the amino acid sequence of AAV3 (SEQ ID NO:3) or the equivalent amino acid residue in AAV1 (SEQ ID NO:1), AAV2 (SEQ ID NO:2), AAV6 (SEQ ID NO:4), AAV7 (SEQ ID NO:5), AAV8 (SEQ ID NO:6), AAV9 (SEQ ID NO:7), or AAVrh10 (SEQ ID NO:8).

[0017] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises modifications at amino acid residues S263, S269, A237 (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of AAV9 (SEQ ID NO:9) or the equivalent amino acid residue in AAV1 (SEQ ID NO:1), AAV2 (SEQ ID NO:2), AAV3 (SEQ ID NO:3), AAV6 (SEQ ID NO:4), AAV7 (SEQ ID NO:5), AAV8 (SEQ ID NO:6), or AAVrh10 (SEQ ID NO:8).

[0018] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises the sequence of any one of SEQ ID NO:9 to SEQ ID NO:34.

[0019] The present disclosure further provides an AAV capsid comprising the capsid protein of the present disclosure, and a viral vector comprising the AAV capsid of the present disclosure. In some embodiments, the viral vector comprises an AAV capsid of the present disclosure and a nucleic acid comprising at least one terminal repeat sequence, wherein the nucleic acid is encapsidated by the AAV capsid.

[0020] The present disclosure further provides pharmaceutical compositions comprising the AAV capsids and / or viral vectors disclosed herein.

[0021] Also provided herein are methods of introducing a nucleic acid molecule into a cell comprising contacting the cell with a disclosed viral vector, and methods of delivering a nucleic acid molecule to a subject comprising administering a disclosed viral vector to the subject.

[0022] In addition, the present disclosure provides a method for selectively delivering a nucleic acid molecule of interest to a neuronal cell, comprising contacting the neuronal cell with a viral vector of the present invention, wherein the viral vector comprises a nucleic acid molecule of interest.

[0023] In yet another embodiment, the present disclosure provides a method for treating a neurological disorder or defect in a subject, comprising administering to the subject a viral vector of the present disclosure, wherein the viral vector comprises a nucleic acid molecule encoding a therapeutic protein or therapeutic RNA effective in treating the neurological disorder or defect.

[0024] These and other aspects are addressed in greater detail in the description set forth below. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 Quantification of cortical neuron transduction. The dose was 5×10 11The vector (AAV1, AAV1R6 or AAV1R7) containing CBh-scGFP or PBS as a negative control was systemically administered to 6-8 week old female BL6 mice by tail vein injection. Mice were sacrificed 21 days after injection, and tissues were harvested, fixed and sliced. Tissues were immunostained for GFP using DAB substrate, and GFP expression was observed by slide scanning and ImageScope software. GFP-positive neurons in the cerebral cortex were manually counted, quantified and averaged in multiple coronal brain sections throughout each mouse. For AAV1, N = 2; for AAV1R6 and AAV1R7, n = 3.

[0027] Figure 2 . Transform the brain vasculature and express in neurons. AAV vectors containing Cbh-scGFP transgene were injected into the brain at 5×10 11 The doses of vg were administered to C57 / B16 mice by tail vein injection. Mice were sacrificed 21 days after injection, tissues were harvested, fixed, sectioned, DAB stained for GFP detection, imaged by Aperio Scanner and processed with ImageScope software. Abbreviations: cortex (CTX), motor cortex (MCT), striatum (STR), hippocampus (HC), dentate gyrus (DG). N=3.

[0028] Figure 3 . Liver de-targeting. AAV vectors containing CBA-luciferase transgene were injected at 1×10 11 The dose of vg was administered to C57 / B16 mice by tail vein injection. Mice were sacrificed 14 days after injection, tissues were harvested, minced, lysed and subjected to luciferase assay to detect relative transduction levels of brain, heart, liver and spinal cord tissues. Data were normalized to relative light units per gram of tissue. N=3.

[0029] Figure 4 Phylogenetic and structural analysis of the AC.AAV1 / rh.10 domain-swapped capsid library. Figure 4 A. Schematic representation of a representative set of AAV1 / rh.10 chimeric capsids isolated from the library demonstrating the sequence diversity at the amino acid level of domain swapping obtained by shuffling. Individual parental or chimeric capsids are listed vertically, while VP1 capsid sequences with different domain swaps are shown horizontally from the N-terminus on the left to the C-terminus on the right. AAV1-derived residues are shown in gray, AAVrh.10 residues in turquoise, and common residues between the two are shown in black. Figure 4B. Neighbor-joining phylogeny of VP1 capsid sequences of AAV1 / rh.10 chimeric capsids. Capsid amino acid sequences were aligned with ClustalW and phylogenies were generated using the neighbor-joining method. Amino acid distances were calculated using Poisson correction and expressed as units of the number of amino acid substitutions per site. The tree is drawn to scale with branch lengths identical to the branch lengths of the evolutionary distances used to infer the tree. Bootstrap values ​​were calculated using 1000 replicates and the percentage of replicate trees in which related taxa clustered together is shown next to the branches. Figure 4 C. Three-dimensional surface model of the capsid subunit trimer / 3-fold symmetry axis region of parental and representative chimeric AAV capsid mutants selected for in vivo screening. Amino acid residues derived from AAV1 are shown in gray, while residues derived from AAVrh.10 are shown in cyan-green. PyMol was used to visualize and generate the structural model.

[0030] Figure 5 In vivo screening generated AAV1 / rh.10 chimeras that were able to cross the blood-brain barrier after intravenous administration. 11 Scans of immunostained brain sections 3 weeks after administration of doses of vg by tail vein injection show GFP expression in the cerebral cortex mediated by parental or chimeric vectors packaging the CBh-scGFP transgene (or PBS in the case of mock treatment). Gross coronal brain sections (upper panels) represent cuboid regions of the cortex seen in the insets shown for each parental or chimeric vector, representing their respective transduction profiles. Scale bar = 100 μm.

[0031] Figure 6 In vivo screening of AG.AAV1 / rh.10 chimeras for their ability to cross the blood-brain barrier and transduce various brain regions after intravascular administration. Mice received a dose of 5 × 10 11 vg parental (AAV1 or AAVrh.10) or chimeric vectors packaging the CBh-scGFP transgene. Immunostained and imaged mouse brain sections showing GFP expression 21 days after injection, as shown by black / dark brown staining. Scale bar = 100 μm. Overall coronal brain sections at the top of the figure represent the various brain regions shown in the inset: MCT, motor cortex ( Figure 6 A); HC, hippocampus ( Figure 6 B); DG, dentate gyrus ( Figure 6 C); TH, thalamus ( Figure 6 D); HY, hypothalamus ( Figure 6 E); STR, striatum ( Figure 6 F); Amg, amygdala ( Figure 6 G). For each type, n=3.

[0032] Figure 7AH. CNS transduction profiles of AAV1R6 and AAV1R7 in the brain compared to parental serotypes AAV1 and AAVrh.10. For parental serotypes AAV1 and AAVrh.10 (left column), and for AAV1R6 and AAV1R7 (right column), 5×10 11 Three weeks after tail vein injection of an AAV vector packaging the CBh-scGFP transgene at a dose of 100 vg, transduction profiles were demonstrated across various brain regions, including the motor cortex ( Figure 7 A), cerebral (somatosensory) cortex ( Figure 7 B) Hippocampus Figure 7 C) dentate gyrus ( Figure 7 D) thalamus Figure 7 E) Hypothalamus ( Figure 7 F), striatum ( Figure 7 G) and amygdala ( Figure 7 H). Scale bar = 100 μm.

[0033] Figure 8 AH. Quantitative comparison of neuronal and glial transduction levels of parental and chimeric capsid variants. 11 The relative neuronal transduction levels 3 weeks after administration of vectors packaging the CBh-scGFP transgene via tail vein injection were quantified by counting the number of transduced neurons and glia per brain region per 50 μm coronal section, identified based on morphology. Transduction of parental serotypes AAV1 and AAVrh.10 and chimeric variants AAV1R6 and AAV1R7 across various brain regions including the motor cortex ( Figure 8 A) Cerebral (somatosensory) cortex ( Figure 8 B) Hippocampus Figure 8 C) dentate gyrus ( Figure 8 D) thalamus Figure 8 E) Hypothalamus ( Figure 8 F), striatum ( Figure 8 G) and amygdala ( Figure 8 H). Error bars represent standard deviation (n> or = 3). Unpaired two-tailed T-test and one-way ANOVA with Welch correction were used to demonstrate statistical significance of neuronal and glial transduction in each group relative to AAV1, and differences between means were demonstrated to be statistically significant, respectively. ns, non-significant; *, P < 0.05.

[0034] Fig. 9 AF. Structural analysis of AAV1R6 chimeric capsid variants. Fig. 9A) Sequence alignment of AAV1R6 with AAV1 & AAVrh.10 highlights amino acid residues uniquely derived from AAVrh.10 (AAV1R6 numbering) (shown in black letters and highlighted in blue). Conserved residues are shown in red letters and highlighted in yellow, while non-conserved equivalent residues on AAV1 are shown in black or green text and highlighted in green or white. Chimeric AAV1R6 VP3 subunit ( Fig. 9 B) The 3D structural model of the monomer was generated using SWISS-MODEL, where the crystal structure of AAV8 was used as a template for homology modeling (PDBID: 2QAO). Fig. 9 C) trimer dimer / 2-fold symmetry axis, ( Fig. 9 D) trimer / three-fold symmetry axis, ( Fig. 9 E) pentamer / 5-fold symmetry axis and ( Fig. 9 F) Surface model representing the surface of the complete AAV1R6 capsid (60-mer) generated by the VIPERdb oligomer generator and visualized using PyMol. Residues derived from AAV1 are colored in gray, while residues derived from AAVrh.10 are clustered at the base of the protrusions at the 3-fold symmetry axis, the depressions at the 2-fold symmetry axis, and the 5-fold hole, colored in cyan.

[0035] Fig.10 AB. Relative cardiac and liver transduction of AAV1R6 and AAV1R7 compared with the parental capsid. 5 × 10 11 Parental (AAV1 or AAVrh.10) or chimeric (AAV1R6 or AAV1R7) vectors packaging the CBh-scGFP transgene were administered at 1:1 dose of vg. Heart and liver sections were immunostained for GFP and imaged 21 days after injection. Fig.10 A. GFP fluorescence in heart (upper panels) and liver (lower panels) tissues in mice treated with PBS (mock), AAV1, AAVrh.10, AAV1R6, or AAV1R7. Fig.10 B. For each treatment, the transduction level of the heart (top) and liver (bottom) was measured by quantifying the relative fluorescence across multiple images taken. The bar represents the range from the lowest value to the highest value, and the center line represents the mean across the samples. The relative fluorescence was normalized to the mock-treated tissue. The error bars represent the standard deviation (n=3). For each group, one-way ANOVA and unpaired two-tailed T test with Welch correction were performed and the significance relative to AAVrh.10 is shown. ns, non-significant. *, P<0.05.

[0036] Fig.11AH. Rational design and functional mapping of a minimal AAVrh.10 footprint for crossing the BBB. Fig.11 A Sequence alignment of AAV1RX with AAV1 and AAVrh.10 showing the numbered amino acid residues within and near the neurotropic footprint. Conserved residues are highlighted in yellow, residues constituting the footprint are highlighted in cyan, and non-conserved residues are highlighted in green or white. Structural models of engineered AAV1RX chimeric capsids were generated using SWISS-MODEL software for homology-based modeling, and oligomers were generated using VIPERdb. PyMol was used to generate monomers of the AAV1RX VP3 subunit ( Fig.11 B), trimer dimer / 2-fold symmetry axis ( Fig.11 C), trimer / three-fold symmetry axis ( Fig.11 D), pentamer / 5-fold symmetry axis ( Fig.11 E) and complete capsid (60-mer) ( Fig.11 F) Model of the rendered surface. Amino acids derived from AAV1 and homologous between AAV1 and AAVrh.10 are indicated in grey, whereas residues comprising the neurotropic footprint from AAVrh.10 for crossing the BBB are indicated in green cyan. Fig.11 G. Stereoscopic roadmap projection showing the neural footprint observed along the three-fold symmetry axis down the AAV1RX capsid and generated using RIVEM. Only surface exposed amino acid residues are shown, with the boundaries between each depicted with black lines. Green areas depict topological protrusions on the three-fold symmetry axis, while blue areas represent topological depressions. Key amino acid residues of this footprint are recolored in magenta (AAVrh.10VP1 numbering). Fig.11 H. CNS transduction profile of AAV1RX packaging CBh-scGFP transgene, where AAV1RX was delivered at 5×10 11 The doses of .vg were administered by tail vein injection. Sections taken 21 days after injection were immunostained and imaged. Scale bar = 100 μm.

[0037] Fig.12 AH. Peripheral tissue transduction and biodistribution of AAV1R6, AAV1R7, and AAV1RX after intravenous administration. 11 The dose of vg was injected into mice via tail vein. Two weeks after injection, the expression level of luciferase reporter gene transgene was quantified ( Fig.12 A, 12C, 12E, 12G) and biodistribution of viral genome copies in various tissues ( Fig.12B, 12D, 12F, 12H). Luciferase expression levels were normalized to grams of tissue lysate and expressed as relative light units. Vector genome (vg) copies were normalized to mouse lamin B (mLamB), an endogenous housekeeping gene, and expressed as vg copies per cell. Error bars represent standard deviations (n=3 for luciferase assays; n=4 for biodistribution). For each group, one-way ANOVA and unpaired two-tailed T-tests with Welch correction were performed and significance relative to AAVrh.10 is shown. ns, non-significant. *, P<0.05.

[0038] Fig.13 AH. Quantification of the levels of AAV1RX-mediated neuronal and glial transduction compared with the parental and other chimeric capsid variants. Mice received a dose of 5 × 10 11 vg's parental (AAV1 or AAVrh.10) or a chimeric vector packaging the CBh-scGFP transgene. At 3 weeks post-injection, brains were harvested, sectioned, immunostained for GFP, and imaged. Relative neuronal and glial transduction levels were immunostained for GFP and imaged. Relative neuronal and glial transduction levels were quantified by counting the number of transduced neurons and glia per region per 50 μm coronal section, identified based on morphology. Transduction levels of AAV1RX across various regions, including the motor cortex ( Fig.13 A) Cerebral cortex ( Fig.13 B) Hippocampus Fig.13 C) dentate gyrus ( Fig.13 D) thalamus Fig.13 E) Hypothalamus ( Fig.13 F), striatum ( Fig.13 G) and amygdala ( Fig.13 H). Error bars represent standard deviation (n=3). Unpaired two-tailed T-test with Welch correction was used to demonstrate statistical significance for each group relative to AAV1. ns: statistically non-significant; *, P<0.05. One-way ANOVA was also used to demonstrate that the differences between means were statistically significant. *, P<0.05 for neuronal and glial transduction across all brain regions shown herein.

[0039] Fig.14.Sequence alignment of the 1RX footprint and variable region I (VR-1) across common AAV serotypes. Sequence alignment of AAV1RX with common AAV serotypes highlights the amino acid residues of the 1RX footprint (VP1 numbering) in the larger context of variable region I (VR-1) compared to common native AAV serotypes. Black lines above and below mark specific residues within the 1RX footprint. Key: Identical residues across serotypes are indicated by red letters on a yellow background; conserved residues are indicated by blue letters on a cyan background; similar residues are indicated by black letters on a green background; weakly similar residues are indicated by green letters on a white background; dissimilar residues are indicated by black letters on a white background. This sequence alignment was generated using Vector NTI Advance 11.5.2 software.

[0040] Fig.15 .Sequence alignment of AAV1, AAV1R7 and AAVrh.10VP1 capsid proteins. DETAILED DESCRIPTION OF THE INVENTION

[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art to which the present disclosure belongs. The technology used herein is only for the purpose of describing specific embodiments and is not restrictive. All publications, patent applications, patents and other references mentioned herein are incorporated herein by reference in their entirety.

[0043] definition

[0044] The following terms are used in this specification and the appended claims:

[0045] Unless the context clearly indicates otherwise, the singular forms "a", "an" and "the" are intended to include the plural forms as well.

[0046] Further, when referring to a measurable value such as an amount of the length of a polynucleotide or polypeptide sequence, dosage, time, temperature, etc., the term "about" as used herein is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5% or even ±0.1% of the particular amount.

[0047] Also as used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of a combination when construed in the alternative ("or").

[0048] As used herein, the transition phrase “consisting essentially of” means that the scope of a claim should be interpreted to include the specified substances or steps recited in the claim, “as well as those essentially Does not affect the claimed invention Basics of and Novel ' Those characteristics'. See In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) (emphasis in the original); see also MPEP §2111.03. Therefore, when used in the claims herein, the term "consisting essentially of is not intended to be interpreted as equivalent to "comprising."

[0049] It is specifically intended that the various features of the capsid proteins, vectors, compositions and methods described herein can be used in any combination unless the context dictates otherwise.

[0050] Furthermore, the present disclosure also contemplates that in some embodiments, any feature or combination of features described herein may be excluded or omitted.

[0051] To further illustrate, for example, if the specification states that a particular amino acid can be selected from A, G, I, L, and / or V, such a sentence also indicates that the amino acid can be selected from any subset of these amino acids, (e.g., A, G, I, or L; A, G, I, or V; A or G; only L; etc.), as if each such subset is expressly set forth herein. In addition, such a sentence also indicates that protection for one or more of the specified amino acids can be disclaimed. For example, in a particular embodiment, the amino acid is not A, G, or I; is not A; is not G or V; etc., if each such possible disclaimer is expressly set forth herein.

[0052] As used herein, the term "reduced" and like terms means a decrease of at least about 25%, 35%, 50%, 75%, 80%, 85%, 90%, 95%, 97% or more relative to a control or reference.

[0053] As used herein, the terms "increase," "enhance," and the like refer to an increase or enhancement of at least about 5%, 10%, 20%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500% or more relative to a control or reference.

[0054] The term "parvovirus" as used herein encompasses the Parvoviridae family, including autonomously replicating parvoviruses and dependent viruses. Autonomous parvoviruses include members of the genus Parvovirus, the genus Erythrovirus, the genus Densovirus, the genus Iteravirus, and the genus Contravirus. Exemplary autonomous parvoviruses include, but are not limited to, minute viruses of mice, bovine parvovirus, canine parvovirus, chicken parvovirus, feline panleukopenia virus, feline parvovirus, goose parvovirus, H1 parvovirus, duck parvovirus, B19 virus, and any other autonomous parvovirus known or discovered later. Other autonomous parvoviruses are known to those skilled in the art. See, for example, BERNARDN.FIELDS et al., VIROLOGY, Vol. 2, Chapter 69 (4th edition, Lippincott-Raven).

[0055] As used herein, the term "adeno-associated virus" (AAV) includes, but is not limited to, AAV type 1, AAV type 2, AAV type 3 (including types 3A and 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAVrh10, AAV type 11, AAV type 12, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, and any other AAV now known or later discovered. See, e.g., BERNARD N. FIELDS et al., VIROLOGY, Vol. 2, Chapter 69 (4th ed., Lippincott-Raven). Many AAV serotypes and clades have been identified (see, e.g., Gao et al. (2004) J. Virology 78:6381-6388; Moris et al. (2004) Virology 33:375-383; and Table 1).

[0056] The genomic sequences of various serotypes of AAV and autonomous parvoviruses, as well as the sequences of native terminal repeats (TRs), Rep proteins, and capsid subunits are known in the art. Such sequences can be found in the literature or in publications such as See, e.g., GenBank Accession Nos. NC_044927, NC_002077, NC_001401, NC_001729, NC_001863, NC_001829, NC_001862, NC_000883, NC_001701, NC_001510, NC_006152, NC_006261, AF063497, U89790, AF043303, A F028705, AF028704, J02275, J01901, J02275, X01457, AF288061, AH009962, AY028226, AY028223, NC_001358, NC_001540, AF513851, AF513852, AY530579; the disclosures of which are incorporated herein by reference for teaching nucleic acid and amino acid sequences of parvoviruses and AAVs. See also, e.g., Srivistava et al. (1983) J. Virology 45:555; Chiorini et al. (1998) J. Virology 71:6823; Chiorini et al. (1999) J. Virology 73:1309; Bantel-Schaal et al. (1999) J. Virology 73:939; Xiao et al. (1999) J. Virology 73:3994; Muramatsu et al. (1996) Virology 221:208; Shade et al. (1986) J. Virol. 58:921; Gao et al. (2002) Proc. Nat. Acad. Sci. USA 99:11854; Moris et al. (2004) Virology 33-:375-383; International Patent Publication Nos. WO 00 / 28061, WO 99 / 61601, WO 98 / 11244; and U.S. Patent No. 6,156,303; the disclosures of which are incorporated herein by reference for teaching nucleic acid and amino acid sequences of parvoviruses and AAV. See also Table 1.

[0057] The capsid structures of autonomous parvoviruses and AAV are described in more detail in BERNARD N. FIELDS et al., VIROLOGY, Vol. 2, Chapters 69 and 70 (4th ed., Lippincott-Raven). See also, descriptions of the crystal structures of AAV2 (Xie et al. (2002) Proc. Nat. Acad. Sci. 99:10405-10), AAV4 (Padron et al. (2005) J. Virol. 79:5047-58), AAV5 (Walters et al. (2004) J. Virol. 78:3361-71), and CPV (Xie et al. (1996) J. Mol. Biol. 6:497-520; Tsao et al. (1991) Science 251:1456-64; Drouin et al. (2013) Future Virol. 8(12):1183-1199).

[0058] The term "tropism" as used herein refers to the preferential entry of a virus into certain cells or tissues, optionally after which a sequence carried by the viral genome in the cell is expressed (e.g., transcribed and, optionally translated), e.g., for a recombinant virus, to express a heterologous nucleic acid of interest. One skilled in the art will appreciate that in some embodiments, transcription of a heterologous nucleic acid sequence from the viral genome will not be initiated in the absence of a trans-acting factor, e.g., for an inducible promoter or other regulated nucleic acid sequence. In the case of a recombinant AAV (rAAV) genome, gene expression from the viral genome can be from a stably integrated provirus and / or from a non-integrated episome, as well as any other form that the virus can take within the cell.

[0059] As used herein, "systemic tropism" and "systemic transduction" (and equivalent terms) indicate that the viral capsid or viral vector of the present disclosure exhibits tropism and / or transduction for systemic tissues (e.g., brain, lung, skeletal muscle, heart, liver, kidney, and / or pancreas, respectively. In embodiments, systemic transduction of the central nervous system (e.g., brain, neural cells, etc.) is observed. In other embodiments, systemic transduction of myocardial tissue is achieved.

[0060] Unless otherwise indicated, "efficient transduction" or "efficient tropism" or similar terms can be determined by reference to an appropriate control (e.g., at least about 50%, 60%, 70%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 350%, 400%, 500% or more transduction or tropism, respectively, of a control). In a specific embodiment, the viral vector efficiently transduces or has efficient tropism for neuronal cells and cardiomyocytes. Appropriate controls will depend on a variety of factors, including the desired tropism profile.

[0061] Similarly, a virus "cannot efficiently transduce" or "does not have efficient tropism" or similar terms for a target tissue can be determined by reference to an appropriate control. In specific embodiments, the viral vector cannot efficiently transduce (i.e., does not have efficient tropism) for liver, kidney, gonads, and / or germ cells. In specific embodiments, the undesired transduction of a tissue (e.g., liver) is 20% or less, 10% or less, 5% or less, 1% or less, 0.1% or less compared to the transduction level of a desired target tissue (e.g., cells of the central nervous system; cardiomyocytes).

[0062] Unless otherwise indicated, the term "polypeptide" as used herein encompasses both peptides and proteins.

[0063] A "polynucleotide" is a sequence of nucleotide bases, and may be RNA, DNA, or a DNA-RNA hybrid sequence (including naturally occurring and non-naturally occurring nucleotides), but in representative embodiments is a single-stranded or double-stranded DNA sequence.

[0064] As used herein, an "isolated" polynucleotide (e.g., "isolated DNA" or "isolated RNA") means a polynucleotide that is at least partially separated from at least some other components of a naturally occurring organism or virus (e.g., cellular or viral structural components or other polypeptides or nucleic acids with which the polynucleotide is normally found). In representative embodiments, the "isolated" nucleic acid molecule is enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more, compared to the starting material.

[0065] Likewise, an "isolated" polypeptide means a polypeptide that is at least partially separated from at least some other components of a naturally occurring organism or virus (e.g., cellular or viral structural components or other polypeptides or nucleic acids with which the polypeptide is normally found in association). In representative embodiments, the "isolated" polypeptide is enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more compared to the starting material.

[0066] As used herein, by "isolating" or "purifying" (or grammatical equivalents) a viral vector, it is meant that the viral vector is at least partially separated from at least some other components in the starting material. In representative embodiments, the "isolated" or "purified" viral vector is enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more compared to the starting material.

[0067] As used herein, "neuronal cells" include sensory neurons, pseudomonopolar neurons, motor neurons, multipolar neurons, interneurons, and / or bipolar neurons located in brain substructures (e.g., cortex, motor cortex, hippocampus, hypothalamus, striatum, basal ganglia, amygdala, cerebellum, dorsal root ganglia, and / or spinal cord).

[0068] A "therapeutic protein" is a protein that is capable of alleviating, reducing, preventing, delaying and / or stabilizing symptoms caused by a deficiency or defect of the protein in a cell or subject, and / or otherwise confers a benefit to a subject.

[0069] As used herein, "therapeutic RNA molecules" or "functional RNA molecules" can be antisense nucleic acids, ribozymes (e.g., as described in U.S. Pat. No. 5,877,022), RNA that affects spliceosome-mediated trans-splicing (see, Puttaraju et al. (1999) Nature Biotech. 17:246; U.S. Pat. No. 6,013,487; U.S. Pat. No. 6,083,702), interfering RNA (RNAi) including siRNA, shRNA or miRNA (which mediates gene silencing) (see, Sharp et al., (2000) Science 287:2431), and any other non-translated RNA such as "guide" RNA (Gorman et al. (1998) Proc. Nat. Acad. Sci. USA 95:4929; U.S. Pat. No. 5,869,248 to Yuan et al.), etc., as known in the art.

[0070] The term "treating" (and grammatical variations thereof) means that the severity of the subject's condition is reduced, at least partially ameliorated or stabilized, and / or some relief, alleviation, reduction or stabilization of at least one clinical symptom is achieved, and / or there is a delay in the progression of the disease or disorder.

[0071] The term "prevent" (and grammatical variations thereof) refers to preventing and / or delaying the onset of and / or reducing the severity of the onset of a disease, disorder, and / or clinical symptom in a subject relative to what would occur in the absence of the methods of the present disclosure. Prevention can be complete, such as the complete absence of a disease, disorder, and / or clinical symptom. Prevention can also be partial, such that the onset and / or severity of the onset of a disease, disorder, and / or clinical symptom in a subject is less than what would occur in the absence of the present disclosure.

[0072] As used herein, a "therapeutically effective" amount is an amount sufficient to provide some improvement or benefit to a subject. Alternatively, a "therapeutically effective" amount is an amount that provides some relief, alleviation, reduction, and / or stabilization in at least one clinical symptom of a subject. One skilled in the art will appreciate that the therapeutic effect need not be complete or curative, as long as some benefit is provided to the subject.

[0073] As used herein, a "prophylactically effective" amount is an amount sufficient to prevent and / or delay the onset of a disease, disorder, and / or clinical symptom in a subject, and / or reduce and / or delay the severity of the onset of a disease, disorder, and / or clinical symptom, relative to what would occur in the absence of the methods of the present disclosure. Those skilled in the art will understand that the level of prevention need not be complete, as long as some benefit is provided to the subject.

[0074] The terms "heterologous nucleotide sequence" and "heterologous nucleic acid molecule" are used interchangeably herein and refer to nucleic acid molecules and / or nucleotide sequences that are not naturally present in a virus. Typically, a heterologous nucleic acid molecule or nucleotide sequence comprises an open reading frame encoding a protein of interest or a non-translated RNA (e.g., for delivery to a cell or subject).

[0075] As used herein, the term "viral vector", "vector" or "gene delivery vector" refers to a virus (e.g., AAV) particle that functions as a nucleic acid delivery vector and comprises a vector genome (e.g., viral DNA [vDNA]) packaged in a virion. Alternatively, in some cases, the term "vector" may be used to refer to a vector genome / vDNA alone.

[0076] "rAAV vector genome" or "rAAV genome" is a recombinant AAV genome (i.e., vDNA) comprising one or more heterologous nucleic acid sequences. The rAAV vector generally requires only (one or more) cis-terminal repeats (TRs) to produce the virus. All other viral sequences are optional and can be provided in trans (Muzyczka (1992) Curr. Topics Microbiol. Immunol. 158: 97). Typically, the rAAV vector genome retains only one or more TR sequences in order to maximize the size of the transgene that can be effectively packaged by the vector. Structural and non-structural protein coding sequences can be provided in trans (e.g., from a vector, such as a plasmid, and / or by stably integrating the sequence into a packaging cell). In an embodiment, the rAAV vector genome comprises at least one terminal repeat (TR) sequence (e.g., an AAV TR sequence), optionally two TRs (e.g., two AAV TRs), which will generally be located at the 5' and 3' ends of the vector genome and flanked by the heterologous nucleic acid sequence, but not necessarily adjacent thereto. TRs may be identical or different from each other.

[0077] The term "terminal repeat" or "TR" includes any viral terminal repeat sequence or synthetic sequence that forms a hairpin structure and acts as an inverted terminal repeat sequence (i.e., mediates a desired function, such as replication, viral packaging, integration and / or proviral rescue, etc.). TR can be an AAV TR or a non-AAV TR. For example, non-AAV TR sequences, such as sequences of other parvoviruses (e.g., canine parvovirus (CPV), parvovirus of mice (MVM), human parvovirus B-19), or any other suitable viral sequence (e.g., an SV40 hairpin used as an SV40 origin of replication), can be used as a TR, which can be further modified by truncation, substitution, deletion, insertion and / or addition. In addition, TR can be partially or completely synthetic, such as the "double D sequence" described in U.S. Pat. No. 5,478,745 to Samulski et al.

[0078] "AAV terminal repeats" or "AAV TRs" can be from any AAV, including but not limited to serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or any other AAV now known or later discovered (see, e.g., Table 1). The AAV terminal repeats need not have native terminal repeat sequences (e.g., native AAV TR sequences can be altered by insertions, deletions, substitutions, truncations, and / or missense mutations), as long as the terminal repeats mediate the desired function, e.g., replication, viral packaging, integration, and / or proviral rescue, etc.

[0079] The viral vectors of the invention may also be "targeted" viral vectors (e.g., having a targeted tropism) and / or "hybrid" parvoviruses (i.e., in which the viral TR and viral capsid are from different parvoviruses), as described in International Patent Publication No. WO 00 / 28004 and Chao et al. (2000) Molecular Therapy 2:619.

[0080] The viral vectors of the present disclosure may also be duplex parvoviral particles as described in International Patent Publication No. WO 01 / 92551 (the disclosure of which is incorporated herein by reference in its entirety). Thus, in some embodiments, the double-stranded (duplex) genome may be packaged into a viral capsid of the present disclosure.

[0081] Additionally, the viral capsid or genomic elements may contain other modifications including insertions, deletions and / or substitutions.

[0082] As used herein, the term "amino acid" encompasses any naturally occurring amino acid, modified forms thereof, and synthetic amino acids.

[0083] Naturally occurring L-amino acids are shown in Table 3.

[0084] In addition, the non-natural amino acid can be a "non-natural" amino acid as described in Wang et al. Annu Rev Biophys Biomol Struct. 35: 225-49 (2006). These non-natural amino acids can be advantageously used to chemically link the molecule of interest to the AAV capsid protein.

[0085] Modified AAV capsid protein, and viral capsid and viral vector comprising the same.

[0086] The present disclosure provides AAV capsid proteins comprising mutations (i.e., modifications, which may be substitutions or insertions or deletions) in the amino acid sequence, as well as viral capsids and viral vectors comprising the modified AAV capsid proteins. The mutated AAV capsid proteins and the nucleic acids encoding them are not found in nature (i.e., are non-natural), and have neither the sequence of the wild-type sequences found in nature nor the functions of these sequences. In contrast, the inventors have discovered that modifications of the amino acid positions described herein can confer one or more desired properties to the viral vectors comprising the modified AAV capsid proteins, including, but not limited to: (i) selective transduction of neuronal cells after crossing the blood-brain barrier after systemic injection; (ii) simultaneous transduction of cardiac tissue and neural tissue after systemic injection; (iii) de-targeting from the liver, spleen, kidneys and other peripheral organs.

[0087] In specific embodiments, the modified AAV capsid proteins of the present disclosure comprise one or more mutations (i.e., modifications) in the amino acid sequence of a native AAV1 capsid protein or in a corresponding amino acid residue of a capsid protein from another AAV serotype, including but not limited to AAV2, AAV3, AAV6, AAV7, AAV8, AAV9, and AAVrh.10. Amino acid positions in other AAV serotypes or modified AAV capsids that "correspond" to these positions in the native AAV1 capsid protein will be apparent to those skilled in the art and can be identified using sequence alignment techniques (see, e.g., WO 2006 / 066066). Figure 7 ) and / or crystal structure analysis (Padron et al. (2005) J. Virol. 79:5047-58).

[0088] Those skilled in the art will appreciate that for some AAV capsid proteins, the corresponding modifications will be insertions and / or substitutions, depending on whether the corresponding amino acid position is partially or completely present in the virus, or whether it is completely absent. Similarly, when modifying AAV rather than AAV1, specific amino acid positions may differ from those in AAV1 (using VP1 numbering). As discussed elsewhere herein, the corresponding amino acid positions will be apparent to those skilled in the art using well-known techniques.

[0089] As used herein, "mutation" or "modification" in an amino acid sequence includes substitutions, insertions and / or deletions, each of which may involve one, two, three, four, five, six, seven, eight, nine, ten or more amino acids. In certain embodiments, the modification is a substitution. In other embodiments, the modification is an insertion (e.g., of a single amino acid residue between two amino acid residues in an amino acid sequence).

[0090] Thus, in one embodiment, the disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises, consists essentially of, or consists of modifications at amino acid residues S262, A263, S264, T265, A267, and S268, and a single amino acid residue insertion between residues 266 and 267 (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of AAV1 (SEQ ID NO: 1), or the equivalent amino acid residues in AAV2 (SEQ ID NO: 2), AAV3 (SEQ ID NO: 3), AAV6 (SEQ ID NO: 4), AAV7 (SEQ ID NO: 5), AAV8 (SEQ ID NO: 6), AAV9 (SEQ ID NO: 7), or AAVrh10 (SEQ ID NO: 8). In some embodiments, the AAV capsid protein may comprise a modification at amino acid residue H272. In certain embodiments, the modification is S262N, A263G, S264T, T265S, A267S, S268T, H272T, and combinations thereof. In certain embodiments, the single amino acid residue insertion between residues 266 and 267 is a G (designated -267G).

[0091] In some embodiments, the AVV capsid protein of the invention can further comprise, consist essentially of, or consist of modifications at amino acid residues Q148, E152, S157, T162, H272, T326, D328, V330, T331, V341, and S345, and a single amino acid residue insertion between residues 152 and 153 (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of SEQ ID NO: 1 or the equivalent amino acid residue in SEQ ID NO: 2, 3, 4, 5, 6, 7, or 8. In a specific embodiment, the modifications are Q148P, E152R, S157T, T162K, H272T, T326Q, D328E, V330T, T331K, V341I, and S345T. In a specific embodiment, the single amino acid residue insertion between residues 152 and 153 is S (designated as -153S).

[0092] In some embodiments, the AAV capsid protein described above can further comprise, consist essentially of, or consist of modifications of amino acid residues L188, S205, N223, A224, and H272 (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of SEQ ID NO: 1, or the equivalent amino acid residues in SEQ ID NO: 2, 3, 4, 5, 6, 7, or 8. In specific embodiments, the modifications are L188I, S205A, N223S, A224S, and H272T.

[0093] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises, consists essentially of, or consists of modifications at amino acid residues S262, A263, S264, T265, and A267 (VP1 numbering), and a single amino acid residue insertion between residues S268 and N269, wherein the numbering of each residue is based on the amino acid sequence of AAV1 (SEQ ID NO: 1), or the equivalent amino acid residues in AAV2 (SEQ ID NO: 2), AAV3 (SEQ ID NO: 3), AAV6 (SEQ ID NO: 4), AAV7 (SEQ ID NO: 5), AAV8 (SEQ ID NO: 6), AAV9 (SEQ ID NO: 7), or AAVrh10 (SEQ ID NO: 8). In some embodiments, the modification is at least one of S262N, A263G, S264T, T265S, and A267S. In some embodiments, the AAV capsid may further comprise, consist essentially of, or consist of a modification at amino acid residue H272. In some embodiments, the AAV capsid protein may further comprise, consist essentially of, or consist of modifications at amino acid residues Q148, E152, S157, T162, H272, T326, D328, V330, T331, V341, and S345, and a single amino acid residue insertion between residues E152 and P153. In some embodiments, the AAV capsid protein further comprises modifications at amino acid residues L188, S205, N223, A224, and H272. In some embodiments, the modification is at least one of L188I, S205A, N223S, A224S, and H272T. In some embodiments, the amino acid residue insertion between residues S268 and N269 is an insertion of a single T residue. In some embodiments, the amino acid residue insertion between residues E152 and P153 is an insertion of a single S residue.

[0094] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises, consists essentially of, or consists of: modifications resulting in the following amino acid sequence: X at amino acids corresponding to amino acid positions 262 to 265 (VP1 numbering) of the native AAV1 capsid protein (SEQ ID NO: 1); 1 -X 2 -X 3 -X 4 (SEQ ID NO: 35), wherein X 1 is any amino acid except S; 2 is any amino acid except A; 3 is any amino acid except S; 4 is any amino acid other than T. 45. In some embodiments, amino acid X 1 is N, amino acid X 2 is G, amino acid X 3 is T, or amino acid X 4 is S. In some embodiments, amino acid X 1 is N, amino acid X 2 is G, amino acid X 3 is T, amino acid X 4 In some embodiments, the AAV capsid protein further comprises a modification of amino acid residue H272. In some embodiments, the modification is H272T. In some embodiments, the AAV capsid protein further comprises an amino acid residue insertion between amino acid residues S268 and N269. In some embodiments, the amino acid residue insertion is an insertion of a single T residue.

[0095] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises, consists essentially of, or consists of modifications at amino acid residues S262, A263, S264, T265, A267, and H272, and a single amino acid residue insertion between residues S268 and N269, (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of AAV1 (SEQ ID NO: 2) or the equivalent amino acid residues in AAV1 (SEQ ID NO: 1), AAV3 (SEQ ID NO: 3), AAV6 (SEQ ID NO: 4), AAV7 (SEQ ID NO: 5), AAV8 (SEQ ID NO: 6), AAV9 (SEQ ID NO: 7), or AAVrh10 (SEQ ID NO: 8). In some embodiments, the modifications include at least one of S262N, A263G, S264T, T265S, A267G, and H272T. In some embodiments, the native single amino acid residue insertion between residues S268 and N269 is an insertion of a single T residue.

[0096] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises, consists essentially of, or consists of modifications at amino acid residues S262, Q263, S264, A266, S267, and H271, and an insertion of at least one amino acid residue between residues S261 and S262, (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of AAV2 (SEQ ID NO: 2) or the equivalent amino acid residue in AAV1 (SEQ ID NO: 1), AAV3 (SEQ ID NO: 3), AAV6 (SEQ ID NO: 4), AAV7 (SEQ ID NO: 5), AAV8 (SEQ ID NO: 6), AAV9 (SEQ ID NO: 7), or AAVrh10 (SEQ ID NO: 8). In some embodiments, the modifications include at least one of S262T, Q263S, S264G, A266S, S267T, and H271T. In some embodiments, the insertion between residues SS61 and S262 is an insertion of a single amino acid residue. In some embodiments, the insertion between residues S251 and S252 is an insertion of more than one amino acid residue. In some embodiments, the insertion between residues S251 and S252 is an insertion of N and G residues.

[0097] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises, consists essentially of, or consists of modifications at amino acid residues S262, Q263, S264, A266, A267, H271, and a single amino acid residue insertion between residues S261 and S262, wherein the numbering of each residue is based on the amino acid sequence of AAV3 (SEQ ID NO: 3) or the equivalent amino acid residues in AAV1 (SEQ ID NO: 1), AAV2 (SEQ ID NO: 2), AAV6 (SEQ ID NO: 4), AAV7 (SEQ ID NO: 5), AAV8 (SEQ ID NO: 6), AAV9 (SEQ ID NO: 7), or AAVrh10 (SEQ ID NO: 8). In some embodiments, the modifications include at least one of S262T, Q263S, S264G, A266S, A267T, H271T. In some embodiments, the insertion between residues SS61 and S262 is an insertion of a single amino acid residue or more than one amino acid residue. In some embodiments, the insertion between residues S251 and S252 is an insertion of N and G residues.

[0098] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises, consists essentially of, or consists of modifications at amino acid residues S263, S269, A237 (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of AAV9 (SEQ ID NO: 9) or the equivalent amino acid residues in AAV1 (SEQ ID NO: 1), AAV2 (SEQ ID NO: 2), AAV3 (SEQ ID NO: 3), AAV6 (SEQ ID NO: 4), AAV7 (SEQ ID NO: 5), AAV8 (SEQ ID NO: 6), or AAVrh10 (SEQ ID NO: 8). In some embodiments, the modifications include at least one of S263G, S269T, and A273T.

[0099] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises, consists essentially of, or consists of the sequence of any one of SEQ ID NO:9 to SEQ ID NO:34.

[0100] Non-limiting examples of modifications that produce capsid proteins of the present disclosure in AAV serotypes 1, 2, 3, 6, 7, 8, and 9, respectively, are shown in Table 2, where the equivalent amino acid residues in each AAV serotype are identified.

[0101] In further embodiments, the capsid protein of the present disclosure may comprise, consist essentially of, or consist of the amino acid sequence of SEQ ID NO:9 (AAV1RX); the amino acid sequence of SEQ ID NO:10 (AAV2RX); the amino acid sequence of SEQ ID NO:11 (AAV3RX); the amino acid sequence of SEQ ID NO:12 (AAV6RX); the amino acid sequence of SEQ ID NO:13 (AAV7RX); the amino acid sequence of SEQ ID NO:14 (AAV8RX); the amino acid sequence of SEQ ID NO:15 (AAV9RX); the amino acid sequence of SEQ ID NO:16 (AAV1R6); the amino acid sequence of SEQ ID NO:17 (AAV2R6); the amino acid sequence of SEQ ID NO:18 (AAV3R6); the amino acid sequence of SEQ ID NO:19 (AAV6R6); the amino acid sequence of SEQ ID NO:20 (AAV7R6); the amino acid sequence of SEQ ID NO:21 (AAV8R6); the amino acid sequence of SEQ ID NO:22 (AAV8R6); the amino acid sequence of SEQ ID NO:23 (AAV8R6); the amino acid sequence of SEQ ID NO:24 (AAV8R6); the amino acid sequence of SEQ ID NO:25 (AAV8R6); the amino acid sequence of SEQ ID NO:26 (AAV1R6); the amino acid sequence of SEQ ID NO:27 (AAV2R6); the amino acid sequence of SEQ ID NO:28 (AAV3R6); the amino acid sequence of SEQ ID NO:29 (AAV6R6); the amino acid sequence of SEQ ID NO:30 (AAV7R6); the amino acid sequence of SEQ ID NO:31 (AAV8R6); the amino acid sequence of SEQ ID NO:32 (AAV8 In one embodiment, the capsid protein of the present invention has the amino acid sequence of SEQ ID NO:9 (AAV1RX). In one embodiment, the capsid protein of the present invention has the amino acid sequence of SEQ ID NO:16 (AAV1R6). In one embodiment, the capsid protein of the present invention has the amino acid sequence of SEQ ID NO:23 (AAV1R7). In one embodiment, the capsid protein of the present invention has the amino acid sequence of SEQ ID NO:24 (AAV2R7).

[0102] In some embodiments, the present disclosure provides an AAV capsid protein having at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, including all ranges and subranges therebetween, sequence identity to: the amino acid sequence of SEQ ID NO:9 (AAV1RX); the amino acid sequence of SEQ ID NO:10 (AAV2RX); the amino acid sequence of SEQ ID NO:11 (AAV3RX); the amino acid sequence of SEQ ID NO:12 (AAV6RX); the amino acid sequence of SEQ ID NO:13 (AAV7RX); the amino acid sequence of SEQ ID NO:14 (AAV8RX); and the amino acid sequence of SEQ ID NO:15 (AAV9RX).

[0103] In some embodiments, the present disclosure provides an AAV capsid protein having at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, including all ranges and subranges therebetween, sequence identity to the following: the amino acid sequence of SEQ ID NO: 16 (AAV1R6); the amino acid sequence of SEQ ID NO: 17 (AAV2R6); the amino acid sequence of SEQ ID NO: 18 (AAV3R6); the amino acid sequence of SEQ ID NO: 19 (AAV6R6); the amino acid sequence of SEQ ID NO: 20 (AAV7R6); the amino acid sequence of SEQ ID NO: 21 (AAV8R6); the amino acid sequence of SEQ ID NO: 22 (AAV9R6).

[0104] In some embodiments, the present disclosure provides an AAV capsid protein having at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, including all ranges and subranges therebetween, sequence identity to the following amino acid sequence: the amino acid sequence of SEQ ID NO:23 (AAV1R7); the amino acid sequence of SEQ ID NO:24 (AAV2R7); the amino acid sequence of SEQ ID NO:25 (AAV3R7); the amino acid sequence of SEQ ID NO:26 (AAV6R7); the amino acid sequence of SEQ ID NO:27 (AAV7R7); the amino acid sequence of SEQ ID NO:28 (AAV8R7); and the amino acid sequence of SEQ ID NO:29 (AAV9R7).

[0105] The present disclosure also provides an adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises one or more substitutions at all positions or any combination of less than all positions, resulting in an amino acid sequence: 1 -X 2 -X 3-X 4 (SEQ ID NO: 35). In some embodiments, the amino acid sequence modification: X 1 -X 2 -X 3 -X 4 is located at the amino acid corresponding to amino acid positions 262 to 265 (VP1 numbering) of the native AAV1 capsid protein (SEQ ID NO: 1). In some embodiments, X 1 It can be any amino acid except S. In some embodiments, X 2 It can be any amino acid except A. In some embodiments, X 3 It can be any amino acid except S. In some embodiments, X 4 It can be any amino acid except T. In one embodiment, amino acid X 1 is N. In one embodiment, amino acid X 2 is G. In one embodiment, amino acid X 3 is T. In one embodiment, amino acid X 4 is S. In another embodiment, X 1 It is N, X 2 It's G, X 3 is T, and X 4 is S. In some embodiments, X 1 To X 4 One of the residues is not substituted, and the amino acid residue at the unsubstituted position is a wild-type amino acid residue.

[0106] Examples of amino acid residues that can be used to replace the natural amino acids at the various positions described herein are listed in Table 3.

[0107] It should be understood that the substitutions and insertions described in the AAV capsid proteins of the present disclosure may include substitutions and / or insertions with conservative amino acid residues. Such conservative substitutions are well known in the art and include, for example, non-polar amino acids Gly, Ala, Val, Leu, Ile, Met, Phe, Trp and Pro can be substituted for each other; polar amino acids Ser, Thr, Cys, Tyr, Asn and Gln can be substituted for each other; negatively charged amino acids Asp and Glu can be substituted for each other; positively charged amino acids Lys, Arg and His can be substituted for each other, in any combination.

[0108] The present disclosure also provides an AAV capsid comprising a capsid protein of the present disclosure, and a viral vector comprising an AAV capsid of the present disclosure. In some embodiments, the viral vector comprises, consists essentially of, or consists of: a viral vector comprising an AAV capsid of the present disclosure; and a nucleic acid molecule comprising at least one terminal repeat sequence, wherein the nucleic acid is encapsidated by an AAV capsid. In some embodiments, the terminal repeat sequence is an AAV terminal repeat sequence. In some embodiments, the terminal repeat sequence is a non-AAV terminal repeat sequence.

[0109] Also provided herein are compositions comprising the capsid protein and / or viral vector of the present disclosure in a pharmaceutically acceptable carrier.

[0110] The present disclosure also provides several methods, including methods of introducing a nucleic acid molecule into a cell, comprising contacting the cell with a viral vector and / or composition of the present disclosure, e.g., under conditions whereby the viral vector is taken up or internalized by the cell and the nucleic acid molecule introduced by the viral vector is expressed in the cell.

[0111] Also provided herein is a method for delivering a nucleic acid molecule to a subject, comprising administering a viral vector and / or composition of the present disclosure to the subject. In a specific embodiment, the viral vector and / or composition is administered to the central nervous system of the subject. In a specific embodiment, the viral vector and / or composition is delivered across the blood-brain barrier.

[0112] In some embodiments, the viral vectors of the present disclosure may comprise a nucleic acid molecule of interest. In some embodiments, the nucleic acid molecule of interest can encode a therapeutic protein or a therapeutic RNA molecule.

[0113] The present disclosure also provides a method for selectively delivering a nucleic acid molecule of interest to a neuronal cell, which includes contacting the neuronal cell with a viral vector of the present disclosure, wherein the viral vector comprises a nucleic acid molecule of interest. In a further embodiment, the method may additionally include selectively delivering a nucleic acid molecule of interest to a cardiomyocyte, for example, when the method is performed in a subject (e.g., a human subject). In some embodiments, the composition is selectively delivered to a neuronal cell. In some embodiments, the composition is selectively delivered to a cardiomyocyte.

[0114] In another embodiment, the present disclosure provides a method for treating a neurological disorder or defect in a subject, comprising administering to the subject a viral vector of the present disclosure, wherein the viral vector comprises a nucleic acid molecule encoding a therapeutic protein or therapeutic RNA effective in treating the neurological disorder or defect.

[0115] Additionally provided herein are methods for treating a neurological and cardiovascular disorder or defect in a subject comprising administering to the subject a viral vector of the present disclosure, wherein the viral vector comprises a nucleic acid molecule encoding a therapeutic protein or therapeutic RNA effective in treating the neurological and cardiovascular disorder or defect.

[0116] In the methods described herein, the viral vectors and / or compositions of the present disclosure can be administered / delivered to the subject of the present disclosure via a systemic route (e.g., intravenous, intraarterial, intraperitoneal, etc.). In some embodiments, the viral vectors and / or compositions can be administered to the subject via an intracerebroventrical, intracisternal, intraparenchymal, intracranial and / or intrathecal route.

[0117] In some embodiments, systemic administration of viral vectors and / or compositions to subjects results in lower transduction of off-target tissues (e.g., except the central nervous system). In some embodiments of the present disclosure, viral vectors are detargeted from spleen, liver, and / or kidney. In some embodiments, viral vectors are detargeted from splenocytes, hepatocytes, and / or kidney cells. In some embodiments, compared to transduction by AAVrh.10, viral vectors transduce liver, spleen, and / or kidney at a level that is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, wherein viral transduction is optionally determined by luciferase or GFP expression. Preferably, the viral vector transduces the liver, spleen and / or kidney at a level that is at least 50%-100% or 80%-90% reduced compared to transduction by AAVrh.10, wherein viral transduction is optionally determined by luciferase or GFP expression.

[0118] In some embodiments, the viral vector transduces the brain at a level that is increased by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% compared to transduction by AAV1, wherein viral transduction is optionally determined by luciferase or GFP expression. Preferably, the viral vector transduces the brain at a level that is increased by at least 2-fold, 2.5-fold, 3-fold, 4-fold, 4.5-fold, 5-fold, 5.5-fold, 6-fold, 6.5-fold, 7-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold or 10-fold compared to transduction by AAV1, wherein viral transduction is optionally determined by luciferase or GFP expression. In some embodiments, the viral vector selectively transduces neurons.

[0119] The present disclosure contemplates that the modified capsid protein of the present disclosure can be produced by modifying the capsid protein of any AAV known now or discovered later. In addition, the AAV capsid protein to be modified can be a naturally occurring AAV capsid protein (e.g., AAV2, AAV3a or 3b, AAV6, AAV7, AAV8, AAV9, AAVrh.10, or any AAV serotype shown in Table 1), but not so limited. It will be appreciated by those skilled in the art that various operations on AAV capsid proteins are known in the art, and the present disclosure is not limited to the modification of naturally occurring AAV capsid proteins. For example, compared to naturally occurring AAV, the capsid protein to be modified may already have a modification (e.g., derived from naturally occurring AAV capsid proteins, such as AAV2, AAV3a, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and / or AAV12, or any other AAV known now or discovered later). Such AAV capsid proteins are also within the scope of the present disclosure.

[0120] Thus, in certain embodiments, the AAV capsid protein to be modified may be derived from a naturally occurring AAV, but may further comprise one or more foreign sequences (e.g., foreign sequences of a native virus) that have been inserted and / or substituted into the capsid protein and / or have been altered by deletion of one or more amino acids.

[0121] Thus, when referring to a specific AAV capsid protein herein (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 or AAV12 capsid protein or a capsid protein from any AAV serotype shown in Table 1, etc.), it is intended to cover native capsid proteins as well as capsid proteins with changes other than the modifications disclosed herein. These changes include substitutions, insertions and / or deletions. In a specific embodiment, the capsid protein may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, less than 20, less than 30, less than 40, less than 50, less than 60 or less than 70 amino acids inserted therein compared to the native AAV capsid protein sequence (in addition to the insertions of the present invention). In embodiments of the present disclosure, the capsid protein may comprise (in addition to the amino acid substitutions according to the present invention) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, less than 20, less than 30, less than 40, less than 50, less than 60 or less than 70 amino acid substitutions compared to the native AAV capsid protein sequence. In embodiments, the capsid protein may comprise (in addition to the amino acid deletions of the present invention) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, less than 20, less than 30, less than 40, less than 50, less than 60 or less than 70 amino acid deletions compared to the native AAV capsid protein sequence.

[0122] In certain embodiments, the AAV capsid protein has a native AAV capsid protein sequence or has an amino acid sequence that is at least about 90%, 95%, 97%, 98% or 99% similar or identical to a native AAV capsid protein sequence. For example, in certain embodiments, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12 or the like capsid proteins encompass natural AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12 capsid protein sequences and sequences that are at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% similar or identical to natural AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12 capsid protein sequences.

[0123] Methods for determining sequence similarity or identity between two or more amino acid sequences are known in the art. Sequence similarity or identity can be determined using standard techniques known in the art, including but not limited to Smith and Waterman, Adv. Appl. Math. 2, 482 (1981) local sequence identity algorithm, by Needleman and Wunsch J. Mol. Biol. 48, 443 (1970) sequence identity comparison algorithm, by Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85, 2444 (1988) similarity search method, by computerized implementation of these algorithms (Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, WI in GAP, BESTFIT, FASTA and TFASTA), by Devereux et al. Nucl. Acid Res. 12, 387-395 (1984) described best fit sequence program, or by inspection.

[0124] Another suitable algorithm is the BLAST algorithm, which is described in Altschul et al. J. Mol. Biol. 215, 403-410, (1990) and Karlin et al. Proc. Natl. Acad. Sci. USA 90, 5873-5787 (1993). A particularly useful BLAST program is the WU-BLAST-2 program, which is available from Altschul et al. Methods in Enzymology, 266, 460-480 (1996); http: / / blast.wustl / edu / blast / README.html. WU-BLAST-2 uses several search parameters, which are optionally set to default values.

[0125] Furthermore, another useful algorithm is Gapped BLAST as reported by Altschul et al., (1997) Nucleic Acids Res. 25, 3389-3402.

[0126] Modified viral capsids can be used as "capsid vectors" as described, for example, in U.S. Patent No. 5,863,541. Molecules that can be packaged and transferred into cells by modified viral capsids include heterologous DNA, RNA, polypeptides, small organic molecules, metals, or combinations thereof.

[0127] Heterologous molecules are defined as those that are not naturally present in AAV infection, e.g., those that are not encoded by the wild-type AAV genome. In addition, therapeutically useful molecules can be associated with the outside of the chimeric viral capsid for transfer of the molecule into a host target cell. Such associated molecules may include DNA, RNA, small organic molecules, metals, carbohydrates, lipids and / or polypeptides. In one embodiment of the present disclosure, the therapeutically useful molecule is covalently linked (i.e., conjugated or chemically coupled) to the capsid protein. Methods for covalently linking molecules are known to those skilled in the art.

[0128] The modified viral capsids of the present disclosure also find use as templates for further modification of antigenicity to evade neutralizing antibodies in any mammalian serum, such as described in PCT application serial number PCT / 2016 / 054143.

[0129] The modified viral capsids of the present disclosure are also found to be useful in generating (raising) antibodies against novel capsid structures. As another alternative, exogenous amino acid sequences can be inserted into modified viral capsids for antigen presentation to cells, for example, administered to a subject to generate an immune response to the exogenous amino acid sequence.

[0130] In other embodiments, viral capsids may be administered to block certain cell sites prior to and / or simultaneously (e.g., within minutes or hours of each other) administration of a viral vector delivering a nucleic acid molecule encoding a polypeptide, peptide, and / or functional RNA of interest. For example, a capsid of the invention may be delivered to block cell receptors on specific cells, and the delivery vector may be administered subsequently or simultaneously, which may reduce transduction of blocked cells and enhance transduction of other targets.

[0131] According to representative embodiments, the modified viral capsid can be administered to a subject before and / or simultaneously with the modified viral vector according to the present disclosure. In addition, the present disclosure provides compositions and pharmaceutical preparations comprising the modified viral capsid of the present invention; optionally, the composition also comprises the modified viral vector of the present disclosure.

[0132] The present disclosure also provides nucleic acid molecules (optionally, isolated nucleic acid molecules) encoding modified viral capsids and capsid proteins of the present disclosure. Vectors comprising nucleic acid molecules, and cells (in vivo or cultured) comprising nucleic acid molecules and / or vectors of the present disclosure are also provided. Suitable vectors include, but are not limited to, viral vectors (e.g., adenovirus, AAV, herpes virus, alphavirus, vaccinia, poxvirus, baculovirus, etc.), plasmids, bacteriophages, YACs, BACs, etc. Such nucleic acid molecules, vectors, and cells can be used, for example, as reagents (e.g., packaging constructs or helpers of packaging cells) for producing modified viral capsids or viral vectors as described herein.

[0133] Viral capsids according to the invention can be produced using any method known in the art, such as by expression from baculovirus (Brown et al. (1994) Virology 198:477-488).

[0134] The modification of AAV capsid protein according to the present invention is a "selective" modification. This method is in contrast to previous work using whole subunit or large domain exchange between AAV serotypes (see, e.g., International Patent Publication WO 00 / 28004; Hauck et al. (2003) J. Virology 77: 2768-2774; Shen et al. (2007) Mol Ther. 15 (11): 1955-62; and Mays et al. (2013) J Virol. 87 (17): 9473-85). To the best of the inventor's knowledge, the AAV capsid protein of the present invention is the first example of a specific amino acid change that makes it possible to cross the blood-brain barrier.

[0135] In some embodiments, the AAV capsid protein contains specific amino acid changes that make it possible to cross the blood-brain barrier. In some embodiments, the AAV capsid protein comprises 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 amino acid substitutions, wherein the substituted amino acids are derived from AAVrh.10, wherein the amino acid substitutions make it possible to cross the blood-brain barrier. In some embodiments, the AAV capsid protein is derived from the AAV1 capsid protein and comprises 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 amino acid substitutions, wherein the substituted amino acids are derived from AAVrh.10, wherein the amino acid substitutions make it possible to cross the blood-brain barrier. In some embodiments, specific amino acids that enable crossing the blood-brain barrier are 262N, 263G, 264T, 265S, 267G, 268S, 269T, and 273T (VP1 numbering), wherein the numbering of each residue is based on the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:30.

[0136] In some embodiments, the AAV capsid protein contains specific amino acid changes that enable de-targeting from the liver, kidneys, and / or spleen. In some embodiments, the AAV capsid protein comprises 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, wherein the substituted amino acids are derived from AAVrh.10, wherein the amino acid substitutions enable de-targeting from the liver, kidneys, and / or spleen. In some embodiments, the AAV capsid protein is derived from an AAV1 capsid protein and comprises 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acids, wherein the substituted amino acids are derived from AAVrh.10, wherein the amino acid substitutions enable de-targeting from the liver, kidneys, and / or spleen.

[0137] In some embodiments, the replaced amino acid is located in the VR-I region of the capsid. In some embodiments, the replaced amino acid is located on the surface of the capsid. In some embodiments, the replaced amino acid is located at the base of the protrusion of the 3-fold symmetry axis of the capsid. In some embodiments, the replaced amino acid is located in the depression of the 2-fold symmetry axis of the capsid. In some embodiments, the replaced amino acid is located in the VR-II region of the capsid protein, within the DE-loop. In some embodiments, the replaced amino acid is located in the β strand E of the capsid.

[0138] In certain embodiments, "selective" modifications result in the insertion and / or substitution and / or deletion of less than about 20, 18, 15, 12, 10, 9, 8, 7, 6, 5, 4, 3 or 2 contiguous amino acids.

[0139] The modified capsid proteins and capsids of the present disclosure may further comprise any other modifications now known or later identified.

[0140] For example, the AAV capsid proteins and viral capsids of the present disclosure can be chimeric in that they can comprise all or part of a capsid subunit from another virus (optionally another parvovirus or other AAV serotype), e.g., as described in International Patent Publication No. WO 00 / 28004.

[0141] The viral capsid may comprise a targeting sequence (e.g., replaced and / or inserted into the viral capsid) that directs the viral capsid to interact with a cell surface molecule present on a desired target tissue (see, e.g., International Patent Publication No. WO 00 / 28004 and Hauck et al. (2003) J. Virology 77:2768-2774); Shi et al. Human Gene Therapy 17:353-361 (2006) [describing insertion of the integrin receptor binding motif RGD at positions 520 and / or 584 of the AAV capsid subunit]; U.S. Patent No. 7,314,912 [describing insertion of a P1 peptide containing an RGD motif after amino acid positions 447, 534, 573, and 587 of the AAV2 capsid subunit] and International Patent Publication No. WO 2015038958 [describing selective recovery of AAV vectors containing peptide sequences that exhibit increased CNS transduction]). Other positions within the AAV capsid subunit that tolerate insertions are known in the art (eg, positions 449 and 588 described by Grifman et al. Molecular Therapy 3:964-975 (2001)).

[0142] For example, some viral capsids disclosed herein have relatively inefficient tropism for most target tissues of interest (e.g., liver, skeletal muscle, heart, diaphragm, kidney, brain, stomach, intestine, skin, endothelial cells and / or lungs). Targeting sequences can be advantageously incorporated into these low transduction vectors to impart the desired tropism of the viral capsid and optionally the selective tropism for specific tissues. AAV capsid proteins, capsids and vectors containing targeting sequences are described in, for example, International Patent Publication WO 00 / 28004. As another possibility, one or more non-naturally occurring amino acids described by Wang et al. (Annu Rev Biophys Biomol Struct. 35: 225-49 (2006)) can be incorporated into the AAV capsid subunits of the orthogonal sites as a means of redirecting the low transduction vector to the desired target tissue. These unnatural amino acids can be advantageously used to chemically link molecules of interest to AAV capsid proteins, including but not limited to: glycans (mannose-dendritic cell targeting); RGD, bombesin or neuropeptides for targeted delivery to specific cancer cell types; selected from phage-displayed RNA aptamers or peptides targeting specific cell surface receptors (such as growth factor receptors, integrins, etc.). Methods for chemically modifying amino acids are known in the art (see, for example, Greg T. Hermanson, Bioconjugate Techniques, 1st edition, Academic Press, 1996).

[0143] In representative embodiments, the targeting sequence can be a viral capsid sequence (eg, an autonomous parvovirus capsid sequence, an AAV capsid sequence, or any other viral capsid sequence) that directs infection to a specific cell type.

[0144] As another non-limiting example, a heparin binding domain (e.g., a respiratory syncytial virus heparin binding domain) can be inserted or substituted into a capsid subunit that does not normally bind the heparan sulfate (HS) receptor (e.g., AAV 4, AAV5) to allow heparin to bind to the resulting mutant.

[0145] As another non-limiting example, an amino acid footprint that enables binding to glycans (e.g., galactose, sialic acid, mannose, lactose, sulfo-N-lactosamine, galactosamine, glucose, glucosamine, fructose, fucose, gangliosides, chitotriose, chondroitin sulfate, keratin sulfate, dermatan sulfate) can be grafted onto capsid subunits that do not normally bind one or more of the sugars listed above [e.g., U.S. Patent Publication No. US20160017005 entitled Methods and compositions for dual glycan binding AAV vectors].

[0146] B19 infects primary erythroid progenitor cells using erythroglobin as a receptor (Brown et al. (1993) Science 262:114). The structure of B19 has been determined. The B19 capsid has a high resolution (Agbandje-McKenna et al. (1994) Virology 203:106). The region of the B19 capsid that binds to hemoglobin has been mapped between amino acids 399-406 (Chapman et al. (1993) Virology 194:419), the loop region between the β-barrel structure E and F (Chipman et al. (1996) Proc. Nat. Acad. Sci. USA 93:7502). Therefore, the hemoglobin receptor binding domain of the B19 capsid can be replaced into the AAV capsid protein to target the viral capsid or viral vector containing it to erythroid cells.

[0147] In representative embodiments, the exogenous targeting sequence can be any amino acid sequence encoding a peptide that changes the tropism of a viral capsid or viral vector comprising a modified AAV capsid protein. In specific embodiments, the targeting peptide or protein can be naturally occurring, or alternatively can be fully or partially synthesized. Exemplary targeting sequences include ligands and other peptides that bind to cell surface receptors and glycoproteins, such as RGD peptide sequences, bradykinins, hormones, peptide growth factors (e.g., epidermal growth factor, nerve growth factor, fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor I and II, etc.), cytokines, melanocyte stimulating hormone (e.g., α, β or γ), neuropeptides and endorphins, etc., as well as fragments thereof that retain the ability to target cells to their cognate receptors. Other illustrative peptides and proteins include substance P, keratinocyte growth factor, neuropeptide Y, gastrin-releasing peptide, interleukin 2, hen egg white lysozyme, erythropoietin, gonadotropin-releasing hormone, corticostriatin, beta-endorphin, leucine enkephalin, dynorphin B (rimorphin), alpha-neoenkephalin, angiotensin, pneumadin, vasoactive intestinal peptide, neurotensin, motilin and fragments thereof as described above. As another alternative, a binding domain from a toxin (e.g., tetanus toxin or snake toxin, such as alpha-bungarotoxin, etc.) can be substituted into the capsid protein as a targeting sequence. In another representative embodiment, the AAV capsid protein can be modified by replacing "non-classical" import / export signal peptides (e.g., fibroblast growth factor-1 and -2, interleukin 1, HIV-1 Tat protein, herpes virus VP22, etc.) into the AAV capsid protein as described by Cleves (Current Biology 7: R318 (1997)). Also contemplated are peptide motifs that direct specific cellular uptake, such as the FVFLP peptide motif that triggers uptake by hepatocytes.

[0148] Phage display technology, as well as other techniques known in the art, can be used to identify peptides that recognize any cell type of interest.

[0149] The targeting sequence may encode any peptide targeted to a cell surface binding site, including a receptor (e.g., a protein, carbohydrate, glycoprotein, or proteoglycan). Examples of cell surface binding sites include, but are not limited to, heparan sulfate, chondroitin sulfate and other glycosaminoglycans, sialic acid moieties, polysialic acid moieties, glycoproteins and gangliosides, MHC I glycoproteins, carbohydrate components found on membrane glycoproteins, including: mannose, N-acetyl-galactosamine, N-acetyl-glucosamine, fucose, galactose, and the like.

[0150] As yet another alternative, the targeting sequence may be a peptide that can be used for chemical coupling to another molecule targeted for entry into a cell (eg, may contain arginine and / or lysine residues that can be chemically coupled via their R groups).

[0151] The above modifications may be incorporated into the capsid proteins or capsids of the present disclosure in combination with each other and / or with any other modifications now known or later discovered.

[0152] The present disclosure also encompasses viral vectors comprising modified capsid proteins and capsids of the present disclosure. In specific embodiments, the viral vector is a parvoviral vector (e.g., comprising a parvoviral capsid and / or a vector genome), such as an AAV vector (e.g., comprising an AAV capsid and / or a vector genome). In representative embodiments, the viral vector comprises a modified AAV capsid comprising a modified capsid subunit and a vector genome of the present disclosure.

[0153] For example, in representative embodiments, the viral vector comprises: (a) a modified viral capsid (e.g., a modified AAV capsid) comprising a modified capsid protein of the present disclosure; and (b) a nucleic acid comprising a terminal repeat sequence (e.g., AAV TR), wherein the nucleic acid comprising the terminal repeat sequence is encapsidated by the modified viral capsid. The nucleic acid may optionally comprise two terminal repeat sequences (e.g., two AAV TRs).

[0154] In representative embodiments, the viral vector is a recombinant viral vector comprising a heterologous nucleic acid molecule encoding a protein or functional RNA of interest. The recombinant viral vector is described in more detail below.

[0155] Those skilled in the art will understand that the modified capsid proteins, viral capsids and viral vectors disclosed herein exclude those capsid proteins, capsids and viral vectors that have the specified amino acids at the specified positions in their natural state (ie, are not mutants).

[0156] Methods of producing viral vectors

[0157] The present disclosure also provides a method for producing a viral vector of the present invention. In a representative embodiment, the present disclosure provides a method for producing a viral vector, the method comprising providing to a cell: (a) a nucleic acid template comprising at least one TR sequence (e.g., an AAVTR sequence), and (b) an AAV sequence sufficient to replicate the nucleic acid template and sufficient to encapsidate into an AAV capsid (e.g., an AAV rep sequence and an AAV cap sequence encoding an AAV capsid of the present disclosure). Optionally, the nucleic acid template also comprises at least one heterologous nucleic acid sequence. In a specific embodiment, the nucleic acid template comprises two AAV ITR sequences, which are located 5' and 3' of the heterologous nucleic acid sequence (if present), although they do not need to be directly adjacent to it.

[0158] The nucleic acid template and AAV rep and cap sequences are provided under the following conditions: a viral vector comprising the nucleic acid template packaged in an AAV capsid is produced in a cell. The method may further include the step of collecting the viral vector from the cell. The viral vector can be collected from the culture medium and / or by lysing the cells.

[0159] The cell can be a cell that allows the AAV virus to replicate. Any suitable cell known in the art can be used. In a specific embodiment, the cell is a mammalian cell. As another option, the cell can be a trans-complementing packaging cell line that provides the functions missing from the replication-deficient helper virus, such as 293 cells or other E1a trans-complementing cells.

[0160] AAV replication and capsid sequences can be provided by any method known in the art. Current schemes usually express AAV rep / cap genes on a single plasmid. AAV replication and packaging sequences do not need to be provided together, although it may be convenient to do so. AAV rep and / or cap sequences can be provided by any viral or non-viral vector. For example, rep / cap sequences can be provided by hybrid adenovirus or herpes virus vectors (for example, inserted into the E1a or E3 region of the adenovirus vector of the deletion). EBV vectors can also be used to express AAV cap and rep genes. An advantage of this method is that EBV vectors are additional, but always in continuous cell divisions will maintain a high copy number (that is, as an extrachromosomal element stably integrated into the cell, designated as "EBV-based nuclear episomes", see Margolski (1992) Curr. Top. Microbiol. Immun. 158: 67).

[0161] As another alternative, the rep / cap sequence can be stably integrated into the cell.

[0162] Typically, AAV rep / cap sequences are not flanked by TRs to prevent rescue and / or packaging of these sequences.

[0163] The nucleic acid template can be provided to the cell using any method known in the art. For example, the template can be supplied by a non-viral (e.g., plasmid) or a viral vector. In a specific embodiment, the nucleic acid template is supplied by a herpes virus or an adenovirus vector (e.g., inserted into the E1a or E3 region of a missing adenovirus). As another illustration, Palombo et al. (1998) J. Virology 72:5025 describes a baculovirus vector carrying a reporter gene flanking AAV TR. EBV vectors can also be used to deliver templates, as described above for the rep / cap gene.

[0164] In another representative embodiment, the nucleic acid template is provided by a replicating rAAV virus. In yet another embodiment, the AAV provirus comprising the nucleic acid template is stably integrated into the chromosome of the cell.

[0165] In order to enhance viral titer, helper virus functions (e.g., adenovirus or herpes virus) that promote productive AAV infection can be provided to cells. Helper virus sequences necessary for AAV replication are known in the art. Typically, these sequences will be provided by helper adenovirus or herpes virus vectors. Alternatively, adenovirus or herpes virus sequences can be provided by another non-viral or viral vector, for example, as a non-infectious adenovirus miniplasmid that carries all helper genes that promote effective AAV production (such as by Ferrari et al., (1997) Nature Med. 3: 1295, and U.S. Patent Nos. 6,040,183 and 6,093,570).

[0166] In addition, helper virus function can be provided by packaging cells with helper sequences that are either embedded in the chromosome or maintained as stable extrachromosomal elements. Typically, helper virus sequences cannot be packaged into AAV virions, for example, are not flanked by TRs.

[0167] Those skilled in the art will appreciate that it may be advantageous to provide AAV replication and capsid sequences and helper virus sequences (e.g., adenovirus sequences) on a single helper construct. The helper construct may be a non-viral or viral construct. As a non-limiting illustration, the helper construct may be a hybrid adenovirus or a hybrid herpes virus containing the AAV rep / cap genes.

[0168] In a specific embodiment, the AAV rep / cap sequence and the adenovirus helper sequence are supplied by a single adenovirus helper vector. This vector may further comprise a nucleic acid template. The AAV rep / cap sequence and / or the rAAV template may be inserted into a deleted region (e.g., E1a or E3 region) of an adenovirus.

[0169] In a further embodiment, the AAV rep / cap sequences and the adenoviral helper sequences are supplied by a single adenoviral helper vector. According to this embodiment, the rAAV template may be provided as a plasmid template.

[0170] In another illustrative embodiment, the AAV rep / cap sequence and the adenovirus helper sequence are provided by a single adenovirus helper vector, and the rAAV template is integrated into the cell as a provirus. Alternatively, the rAAV template is provided by an EBV vector, which is maintained in the cell as an extrachromosomal element (e.g., as an EBV-based nuclear episome).

[0171] In another exemplary embodiment, the AAV rep / cap sequence and the adenoviral helper sequence are provided by a single adenoviral helper. The rAAV template can be provided as a separate replicating viral vector. For example, the rAAV template can be provided by a rAAV particle or a second recombinant adenoviral particle.

[0172] According to the aforementioned method, the hybrid adenoviral vector generally contains adenoviral 5' and 3' cis sequences (i.e., adenoviral terminal repeats and PAC sequences) sufficient for adenoviral replication and packaging. The AAV rep / cap sequence and rAAV template (if present) are embedded in the adenoviral backbone and flanked by the 5' and 3' cis sequences so that these sequences can be packaged into the adenoviral capsid. As described above, the adenoviral helper sequence and the AAV rep / cap sequence are generally not flanked by the TR so that these sequences are not packaged into the AAV virion.

[0173] Zhang et al. ((2001) Gene Ther. 18:704-12) described a chimeric helper comprising adenovirus and AAV rep and cap genes.

[0174] Herpes viruses can also be used as helper viruses in AAV packaging methods. Hybrid herpes viruses encoding AAV Rep proteins can advantageously facilitate scalable AAV vector production protocols. Hybrid herpes simplex virus type I (HSV-1) vectors expressing AAV-2 rep and cap genes have been described in (Conway et al. (1999) Gene Therapy 6:986 and WO 00 / 17377.

[0175] As another alternative, the viral vectors of the disclosure can be produced in insect cells using baculovirus vectors to deliver the rep / cap genes and the rAAV template as described, for example, in Urabe et al. (2002) Human Gene Therapy 13: 1935-43.

[0176] AAV vector stock solution free of contaminating helper virus can be obtained by any method known in the art. For example, AAV and helper virus can be easily distinguished based on size. AAV can also be separated from helper virus based on affinity chromatography [for example, for heparin substrate (Zolotukhin et al. (1999) Gene Therapy 6:973), or using affinity resin (Wang et al. (2015), Mol Ther Methods Clin Dev 2:15040) or other methods (reviewed in Qu et al. (2015) Curr Pharm Biotechnol.16 (8): 684-95)]. A deleted replication-deficient helper virus can be used so that any contaminating helper virus does not have replication ability. As another alternative, adenovirus helper cells lacking late gene expression can be used, because only adenovirus early gene expression is required to mediate the packaging of AAV virus. Adenovirus mutants defective in late gene expression are known in the art (e.g., ts100K and ts149 adenovirus mutants).

[0177] Recombinant viral vector

[0178] The viral vectors of the present disclosure can be used to deliver nucleic acids to cells in vitro, ex vivo, and in vivo. In particular, viral vectors can be advantageously used to deliver or transfer nucleic acids to cells of animals, including mammals.

[0179] Any heterologous nucleic acid sequence of interest can be delivered in the viral vector of the present disclosure. Nucleic acids of interest include nucleic acids encoding polypeptides and / or functional or therapeutic RNA molecules, including therapeutic (e.g., for medical or veterinary use) or immunogenic (e.g., for vaccines) proteins.

[0180] Therapeutic polypeptides include, but are not limited to, cystic fibrosis transmembrane regulator (CFTR), dystrophin (including mini-dystrophin and micro-dystrophin, see, e.g., Vincent et al. (1993) Nature Genetics 5:130; U.S. Patent Publication No. 2003 / 017131; International Publication WO / 2008 / 088895, Wang et al. Proc. Natl. Acad. Sci. USA 97:13714-13719 (2000); and Gregorevic et al. Mol. Ther. 16:657-64 (2008)), myostatin propeptide, follistatin, activin type II soluble receptor, IGF-1, anti-inflammatory polypeptides such as Ikappa B dominant mutant, sarcospan, utrophin (Tinsley et al. (1996) Nature 384:349), mini-utrophin, coagulation factors (e.g., factor VIII, factor IX, factor X, etc.), erythropoietin, angiostatin, endostatin, catalase, tyrosine hydroxylase, superoxide dismutase, leptin, LDL receptor, lipoprotein lipase, ornithine transcarbamylase, β-globin, α-globin, spectrin, α1-antitrypsin, adenosine deaminase, hypoxanthine guanine antagonist phosphoribosyltransferase, β-glucocerebrosidase, sphingomyelinase, lysosomal hexosaminidase A, branched-chain ketoacid dehydrogenase, RP65 protein, cytokines (e.g., interferon-α, interferon-β, interferon-γ, interleukin-2, interleukin-4, granulocyte-macrophage colony-stimulating factor, lymphotoxin, etc.), peptide growth factors, neurotrophic factors and hormones (e.g., growth hormone, insulin, insulin-like growth factor 1 and 2, platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, nerve growth factor, neurotrophic factor-3 and -4, brain-derived neurotrophic factor, bone morphogenetic protein (bone morphogenic proteins) [including RANKL and VEGF], glial-derived growth factor, transforming growth factor-α and -β, etc.), lysosomal acid α-glucosidase, α-galactosidase A, receptors (such as tumor necrosis growth factor α soluble receptor), S100A1, parvoalbumin, adenylyl cyclase type 6, molecules that regulate calcium handling (e.g., SERCA 2A, inhibitors of PP1 and fragments thereof [e.g., WO 2006 / 029319 and WO 2007 / 100465]), molecules that affect knockdown of G protein-coupled receptor kinase type 2, such as truncated constitutively active bARKct, anti-inflammatory factors such as IRAP, anti-myostatin proteins, aspartic acid enzymes, monoclonal antibodies (including single-chain monoclonal antibodies; exemplary Mabs are Mab), neuropeptides and fragments thereof (e.g., gangliosides, neuropeptide Y (see US7,071,172), angiogenesis inhibitors such as vasohibins and other VEGF inhibitors (e.g., vasohibins 2 [see, WO JP2006 / 073052]). Other illustrative heterologous nucleic acid sequences encode suicide gene products (e.g., thymidine kinase, cytosine deaminase, diphtheria toxin and tumor necrosis factor), proteins that confer resistance to drugs used in cancer treatment, tumor suppressor gene products (e.g., p53, Rb, Wt-1), TRAIL, FAS-ligand and any other polypeptide that has a therapeutic effect in a subject in need thereof. AAV vectors can also be used to deliver monoclonal antibodies and antibody fragments, such as antibodies or antibody fragments directed against myostatin (see, e.g., Fang et al. Nature Biotechnology 23:584-590 (2005)).

[0181] Heterologous nucleic acid sequences encoding polypeptides include those encoding reporter polypeptides (eg, enzymes). Reporter polypeptides are known in the art and include, but are not limited to, green fluorescent protein (GFP), β-galactosidase, alkaline phosphatase, luciferase, and chloramphenicol acetyltransferase genes.

[0182] Optionally, the heterologous nucleic acid molecule can encode a secreted polypeptide (eg, a polypeptide that is a secreted polypeptide in its native state, or a polypeptide that has been engineered to be secreted, eg, by being operably associated with a secretory signal sequence as known in the art).

[0183] Alternatively, in certain embodiments of the present disclosure, the heterologous nucleic acid can encode antisense nucleic acids, ribozymes (e.g., as described in U.S. Pat. No. 5,877,022), RNA that affects spliceosome-mediated trans-splicing (see, Puttaraju et al. (1999) Nature Biotech. 17:246; U.S. Pat. No. 6,013,487; U.S. Pat. No. 6,083,702), interfering RNA (RNAi) including siRNA, shRNA or miRNA (which mediates gene silencing) (see, Sharp et al., (2000) Science 287:2431), and other non-translated RNAs such as "guide" RNAs (Gorman et al. (1998) Proc. Nat. Acad. Sci. USA 95:4929; U.S. Pat. No. 5,869,248 to Yuan et al.), etc. Exemplary non-translated RNAs include RNAi to multidrug resistance (MDR) gene products (e.g., for treating and / or preventing tumors and / or for administration to the heart to prevent chemical damage), RNAi to myostatin (e.g., for Duchenne muscular dystrophy), RNAi to VEGF (e.g., for treating and / or preventing tumors), RNAi to phospholamban (e.g., for treating cardiovascular disease, see, e.g., Andino et al. J. Gene Med. 10:132-142 (2008) and Li et al. Acta Pharmacol. Sin.26:51-55 (2005)); phospholamban inhibitory or dominant negative molecules such as phospholamban S16E (e.g., for the treatment of cardiovascular disease, see, e.g., Hoshijima et al. Nat. Med.8:864-871 (2002)), RNAi against adenosine kinase (e.g., for epilepsy), and RNAi against pathogens and viruses (e.g., hepatitis B and / or hepatitis C virus, human immunodeficiency virus, CMV, herpes simplex virus, human papillomavirus, etc.).

[0184] In addition, nucleic acid sequences that direct alternative splicing can be delivered. To illustrate, an antisense sequence (or other inhibitory sequence) complementary to the 5' and / or 3' splice site of dystrophin exon 51 can be delivered with a U1 or U7 small nuclear (sn) RNA promoter to induce skipping of this exon. For example, a DNA sequence comprising a U1 or U7 snRNA promoter located 5' of the antisense / inhibitory sequence can be packaged and delivered in a modified capsid of the invention.

[0185] Viral vectors can also include heterologous nucleic acid molecules that have homology with and recombinant with loci on the host chromosome. This approach can be used, for example, to correct genetic defects in host cells.

[0186] The present disclosure also provides a viral vector expressing an immunogenic polypeptide (e.g., for vaccination). The nucleic acid molecule may encode any immunogen of interest known in the art, including, but not limited to, immunogens from human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), influenza virus, HIV or SIV gag protein, tumor antigens, cancer antigens, bacterial antigens, viral antigens, and the like.

[0187] The immunogenic polypeptide can be any polypeptide suitable for eliciting an immune response and / or protecting a subject from infection and / or disease (including but not limited to infection and disease by microorganisms, bacteria, protozoa, parasites, fungi and / or viruses). For example, the immunogenic polypeptide can be an orthomyxovirus immunogen (e.g., an influenza virus immunogen, such as an influenza virus hemagglutinin (HA) surface protein or an influenza virus nucleoprotein, or an equine influenza virus immunogen) or a lentivirus immunogen (e.g., an equine infectious anemia virus immunogen, a simian immunodeficiency virus (SIV) immunogen, or a human immunodeficiency virus (HIV) immunogen, such as HIV or SIV envelope GP160 protein, HIV or SIV matrix / capsid protein, and HIV or SIV gag, pol and env gene products). The immunogenic polypeptide can also be an arenavirus immunogen (e.g., a Lassa fever virus immunogen, such as a Lassa fever virus nucleocapsid protein and a Lassa fever envelope glycoprotein), a poxvirus immunogen (e.g., a vaccinia virus immunogen, such as a vaccinia L1 or L8 gene product), a flavivirus immunogen (e.g., a yellow fever virus immunogen or a Japanese encephalitis virus immunogen), a filovirus immunogen (e.g., an Ebola virus immunogen, or a Marburg virus immunogen, such as the NP and GP gene products), a bunyavirus immunogen (e.g., RVFV, CCHF and / or SFS virus immunogens), or a coronavirus immunogen (e.g., an infectious human coronavirus immunogen, such as a human coronavirus envelope glycoprotein, or a porcine transmissible gastroenteritis virus immunogen, or an avian infectious bronchitis virus immunogen). The immunogenic polypeptide can also be a polio immunogen, a herpes immunogen (e.g., CMV, EBV, HSV immunogens), a mumps immunogen, a measles immunogen, a rubella immunogen, a diphtheria toxin or other diphtheria immunogen, a pertussis antigen, a hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, etc.) immunogen, and / or any other vaccine immunogen now known in the art or later identified as an immunogen.

[0188] Alternatively, the immunogenic polypeptide can be any tumor or cancer cell antigen. Optionally, the tumor or cancer antigen is expressed on the surface of a cancer cell. Exemplary cancer and tumor cell antigens are described in SA Rosenberg (Immunity 10:281 (1991)). Other illustrative cancer and tumor antigens include, but are not limited to, BRCA1 gene products, BRCA2 gene products, gp100, tyrosinase, GAGE-1 / 2, BAGE, RAGE, LAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE, SART-1, PRAME, p15, melanoma tumor antigen (Kawakami et al. (1994) Proc. Natl. Acad. Sci. USA 91:3515; Kawakami et al. (1994) J. Exp. Med., 180:347; Kawakami et al. (1994) Cancer Res. 54:3124), MART-1, gp100, tyrosinase, GAGE-1 / 2, BAGE, RAGE, LAGE, NY-ESO-1, CDK-4, β-catenin, MUM-1, caspase-8, KIAA0205, HPVE, SART-1, PRAME, p15, melanoma tumor antigen (Kawakami et al. (1994) Proc. Natl. Acad. Sci. USA 91:3515; Kawakami et al. (1994) J. Exp. Med., 180:347; Kawakami et al. (1994) Cancer Res. 54:3124), MAGE-1, MAGE-2, MAGE-3, CEA, TRP-1, TRP-2, P-15, tyrosinase (Brichard et al. (1993) J. Exp. Med. 178:489); HER-2 / neu gene product (U.S. Pat. No. 4,968,603), CA 125, LK26, FB5 (endosialin), TAG 72, AFP, CA19-9, NSE, DU-PAN-2, CA50, SPan-1, CA72-4, HCG, STN (sialyl Tn antigen), c-erbB-2 protein, PSA, L-CanAg, estrogen receptor, milk fat globulin, p53 tumor suppressor protein (Levine (1993) Ann. Rev. Biochem. 62:623); mucin antigens (International Patent Publication No. WO 90 / 05142); telomerase; nuclear matrix protein; prostatic acid phosphatase; papilloma virus antigens; and / or antigens now known or later discovered to be associated with the following cancers: melanoma, adenocarcinoma, thymoma, lymphoma (e.g., non-Hodgkin's lymphoma, Hodgkin's lymphoma), sarcoma, lung cancer, liver cancer, colon cancer, leukemia, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer, brain cancer, and any other cancer or malignant condition now known or later identified (see, e.g., Rosenberg (1996) Ann. Rev. Med. 47:481-91).

[0189] As another alternative, the heterologous nucleic acid can encode any polypeptide that is desired to be produced in cells in vitro, ex vivo or in vivo. For example, a viral vector can be introduced into cultured cells and the expressed gene product isolated therefrom.

[0190] In other embodiments, the heterologous nucleic acid can encode (a) a site-directed modifying polypeptide based on a zinc finger nuclease or a large range of nucleases or an endonuclease or a TALEN or a CRISPR / Cas system-based nuclease, which contains an RNA binding portion that interacts with a DNA targeting RNA molecule (gRNA), or an mRNA encoding such a polypeptide; (b) one or more guide RNA molecules (gRNA) comprising a nucleotide sequence complementary to a sequence in the target DNA, and a second segment that interacts with the site-directed modifying polypeptide; and / or (c) one or more DNA donor template molecules comprising a single-stranded or double-stranded DNA sequence designed for homologous recombination into a mammalian genome target site. For example, a viral vector can be introduced into isolated stem cells and / or T lymphocytes, cultured cells, in vivo tissues and / or whole organisms, and the expressed gene product can enable editing, destruction, transcriptional activation and / or inhibition of a target gene in the host.

[0191] Those skilled in the art will appreciate that the heterologous nucleic acid molecule of interest can be operably linked to appropriate control sequences. For example, the heterologous nucleic acid molecule can be operably linked to expression control elements such as transcription / translation control signals, replication origins, polyadenylation signals, internal ribosome entry sites (IRES), promoters and / or enhancers, etc.

[0192] Furthermore, regulated expression of the heterologous nucleic acid molecule of interest can be achieved at the post-transcriptional level, for example by regulating alternative splicing of different introns through the presence or absence of oligonucleotides, small molecules and / or other compounds that selectively block splicing activity at specific sites (e.g., as described in WO 2006 / 119137).

[0193] Those skilled in the art will appreciate that a variety of promoter / enhancer elements may be used, depending on the desired level and tissue-specific expression. Promoters / enhancers may be constitutive or inducible, depending on the desired expression pattern. Promoters / enhancers may be native or exogenous, and may be native or synthetic sequences. By exogenous, it is intended that the transcription initiation region is not found in the wild-type host into which the transcription initiation region is introduced.

[0194] In a specific embodiment, the promoter / enhancer element can be native to the target cell or subject to be treated. In a representative embodiment, the promoter / enhancer element can be native to the heterologous nucleic acid sequence. The promoter / enhancer element is usually selected so that it works in the target cell of interest. In addition, in a specific embodiment, the promoter / enhancer element can be a mammalian promoter / enhancer element. The promoter / enhancer element can be constitutive or inducible.

[0195] Inducible expression control elements are generally advantageous in applications where regulation of heterologous nucleic acid sequence expression needs to be provided. Inducible promoter / enhancer elements for gene delivery can be tissue-specific or preferred promoter / enhancer elements, and include muscle-specific or preferred (including heart, bone and / or smooth muscle-specific or preferred), neural tissue-specific or preferred (including brain-specific or preferred), eye-specific or preferred (including retina-specific and cornea-specific), liver-specific or preferred, bone marrow-specific or preferred, pancreas-specific or preferred, spleen-specific or preferred, and lung-specific or preferred promoter / enhancer elements. Other inducible promoter / enhancer elements include hormone-inducible and metal-inducible elements. Exemplary inducible promoter / enhancer elements include, but are not limited to, Tet on / off elements, RU486 inducible promoters, ecdysone-inducible promoters, rapamycin-inducible promoters, and metallothionein promoters.

[0196] In embodiments where the heterologous nucleic acid sequence is transcribed and then translated in the target cell, specific initiation signals are generally included for efficient translation of the inserted protein coding sequence. These exogenous translation control sequences, which may include the ATG initiation codon and adjacent sequences, may be of a variety of origins, both natural and synthetic.

[0197] Viral vectors according to the present invention provide means for delivering heterologous nucleic acids to a wide range of cells, including dividing and non-dividing cells. Viral vectors can be used for delivering nucleic acids of interest to cells in vitro, for example, to produce polypeptides in vitro or for ex vivo gene therapy. Viral vectors can also be used for delivering nucleic acids to subjects in need thereof, for example, to express immunogenic or therapeutic polypeptides or functional RNA, methods. In this way, polypeptides or functional RNAs can be produced in subjects. Subjects may need polypeptides because subjects have a lack of polypeptides. In addition, the method can be implemented because producing polypeptides or functional RNAs in subjects can produce some beneficial effects.

[0198] Viral vectors can also be used to produce polypeptides or functional RNAs of interest in cultured cells or in a subject (e.g., using a subject as a bioreactor to produce a polypeptide or observe the effects of a functional RNA on the subject, e.g., in conjunction with a screening method).

[0199] In general, the viral vectors of the present disclosure can be used to deliver heterologous nucleic acids encoding polypeptides or functional RNAs to treat and / or prevent any disease state for which delivery of a therapeutic polypeptide or functional RNA is beneficial. Illustrative disease states include, but are not limited to: cystic fibrosis (cystic fibrosis transmembrane regulator) and other lung diseases, hemophilia A (factor VIII), hemophilia B (factor IX), thalassemia (β-globin), anemia (erythropoietin) and other blood diseases, Alzheimer's disease (GDF; neprilysin), multiple sclerosis (β-interferon), Parkinson's disease (glial cell line-derived neurotrophic factor [GDNF]), Huntington's disease (RNAi to remove repeats), amyotrophic lateral sclerosis, epilepsy (galanin, neurotrophic factors) and other nervous system diseases, cancer (endostatin, angiostatin, TRAIL, FAS ligands, including stem cells) and other diseases of the nervous system. cytokines that inhibit interferon; RNAi, including RNAi to VEGF or multidrug resistance gene products, mir-26a [e.g., for hepatocellular carcinoma]), diabetes (insulin), muscular dystrophy, including Duchenne dystrophy (dystrophin, mini-dystrophin, insulin-like growth factor I, sarcoglycan [e.g., α, β, γ], RNAi to myostatin, myostatin propeptide, follistatin, activin type II soluble receptor, anti-inflammatory polypeptides such as Ikappa B dominant mutant, sarcospan, utrophin, mini-utrophin, antisense or RNAi to splice junctions in the dystrophin gene to induce exon skipping [see, e.g., WO / 2003 / 095647], RNAi to U7 snRNA to induce exon skipping [see, e.g., WO / 2006 / 021724], and antisense to myostatin or myostatin propeptide) and Becker, Gaucher disease (glucocerebrosidase), Hurler disease (α-L-iduronidase), adenosine deaminase deficiency (adenosine deaminase), glycogen storage diseases (such as Fabry disease [α-galactosidase] and Pompe disease [lysosomal acid α-glucosidase]) and other metabolic disorders, congenital emphysema (α1-antitrypsin), Lesch-Nyhan syndrome (hypoxanthine guanine phosphoribosyltransferase), Niemann-Pick disease (sphingomyelinase), Tay Sachs disease (lysosomal hexosaminidase A), maple syrup urine disease (branched-chain ketoacid dehydrogenase), retinal degenerative diseases (and other diseases of the eye and retina;For example, other inhibitors of PDGF or VEGF or other angiogenesis inhibitors for macular degeneration and / or angiostatin to treat / prevent retinal diseases, such as type I diabetes), diseases of solid organs such as the brain (including Parkinson's disease [GDNF], astrocytoma [endostatin, angiostatin and / or RNAi to VEGF], glioblastoma [endostatin, angiostatin and / or RNAi to VEGF], liver, kidney, heart, including congestive heart failure or peripheral arterial disease (PAD) (e.g., by delivering protein phosphatase inhibitors) I (I-1) and fragments thereof (e.g., I1C), serca2a, zinc finger protein that regulates the phospholamban gene, Barkct, beta2-adrenergic receptor, beta2-adrenergic receptor kinase (BARK), phosphoinositide-3 kinase (PI3 kinase), S100A1, parvoprotein, adenylate cyclase type 6, a protein that affects G protein Molecules that knock down leukocyte-coupled receptor kinase type 2, such as truncated constitutively active bARKct; calsarcin, RNAi against phospholamban; phospholamban inhibitory or dominant negative molecules, such as phospholamban S16E, etc.), arthritis (insulin-like growth factor), joint diseases (insulin-like growth factor 1 and / or 2), intimal hyperplasia (e.g., by delivery of enos, inos), improving survival of cardiac transplants (superoxide dismutase), AIDS (soluble CD4), muscle atrophy (insulin-like growth factor I), renal deficiency (erythropoietin), anemia (erythropoietin), arthritis (anti-inflammatory factors such as IRAP and soluble TNFα receptor), hepatitis (alpha-interferon), LDL receptor deficiency (LDL receptor), hyperammonemia (ornithine transcarbamylase), Krabbe disease (galactocerebrosidase), spinal muscular atrophy (SMA), Batten disease, spinal ataxia (spinal cord ataxia) cerebral ataxias), including Friedreich's ataxia, SCA1, SCA2 and SCA3, phenylketonuria (phenylalanine hydroxylase), autoimmune diseases, etc. The present invention can also be used after organ transplantation to increase the success of transplantation and / or reduce the negative side effects of organ transplantation or adjuvant therapy (e.g., by blocking the production of cytokines by administering immunosuppressants or inhibitory nucleic acids). As another example, bone morphogenetic proteins (including BMP 2, 7, etc., RANKL and / or VEGF) can be administered with bone allografts, for example, after break or surgical resection in cancer patients. ;

[0200] The disclosure can also be used to produce induced pluripotent stem cells (iPS). For example, the viral vector of the disclosure can be used to deliver stem cell-related nucleic acids to non-pluripotent cells, such as adult fibroblasts, skin cells, hepatocytes, kidney cells, adipocytes, cardiomyocytes, nerve cells, epithelial cells, endothelial cells, etc. The nucleic acid encoding the factor associated with stem cells is known in the art. The non-limiting examples of such factors associated with stem cells and pluripotency include Oct-3 / 4, SOX family (e.g., SOX1, SOX2, SOX3 and / or SOX15), Klf family (e.g., Klf1, Klf2, Klf4 and / or Klf5), Myc family (e.g., C-myc, L-myc and / or N-myc), NANOG and / or LIN28.

[0201] The present disclosure may also be practiced for treating and / or preventing epilepsy, stroke, traumatic brain injury, cognitive disorders, behavioral disorders, psychiatric disorders, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and any other neurodegenerative condition that may benefit from or require axon / neuron regeneration or repair.

[0202] In certain embodiments, the present disclosure can be practiced to promote axon regeneration and neuronal repair, restore circuits and / or replenish lost neurons as corrective therapy, for example by targeted regulation or overexpression of stem cell differentiation and reprogramming factors such as FoxJ1, Fox2, NeuroD2, NG2 or Olig2 and / or microRNAs such as miR-137, MiR124, and any other factors or miRNAs involved in neuronal development and differentiation.

[0203] Gene transfer has great potential for understanding and providing treatments for disease states. There are many genetic diseases in which the defective genes are known and have been cloned. In general, the above disease states are divided into two categories: defective states, usually enzyme defective states, which are usually inherited in a recessive manner; and unbalanced states, which may involve regulatory proteins or structural proteins and are usually inherited in a dominant manner. For defective state diseases, gene transfer can be used to bring normal genes into affected tissues for replacement therapy, and to use antisense mutations to generate animal models of the disease. For unbalanced disease states, gene transfer can be used to generate disease states in model systems, which can then be used to resist disease states. Therefore, viral vectors according to the present disclosure allow treatment and / or prevention of genetic diseases.

[0204] The viral vector according to the present invention can also be used to provide functional RNA to cells in vitro or in vivo. The expression of functional RNA in cells, for example, can reduce the expression of cells to specific target proteins. Therefore, functional RNA can be administered to reduce the expression of specific proteins in subjects in need thereof. Functional RNA can also be administered to cells in vitro to regulate gene expression and / or cell physiology, for example, to optimize cell or tissue culture systems or screening methods.

[0205] Additionally, viral vectors according to the present disclosure can be used in diagnostic and screening methods whereby nucleic acids of interest are transiently or stably expressed in cell culture systems, or alternatively, in transgenic animal models.

[0206] The viral vectors of the present invention can also be used for various non-therapeutic purposes, including but not limited to, in protocols for evaluating gene targeting, clearance, transcription, translation, etc., as will be apparent to those skilled in the art. Viral vectors can also be used to evaluate safety (diffusion, toxicity, immunogenicity, etc.). These data, for example, are considered by the U.S. Food and Drug Administration as part of the regulatory approval process prior to evaluating clinical efficacy.

[0207] As another aspect, the viral vectors of the present disclosure can be used to generate an immune response in a subject. According to this embodiment, a viral vector comprising a heterologous nucleic acid sequence encoding an immunogenic polypeptide can be administered to a subject, and the subject initiates an active immune response against the immunogenic polypeptide. The immunogenic polypeptide is as described above. In some embodiments, a protective immune response is elicited.

[0208] Alternatively, the viral vector can be administered to the cell in vitro, and the altered cell is administered to the subject. The viral vector comprising a heterologous nucleic acid is introduced into the cell, and the cell is administered to the subject, wherein the heterologous nucleic acid encoding the immunogen can be expressed, and an immune response in the subject is induced for the immunogen. In a specific embodiment, the cell is an antigen presenting cell (e.g., a dendritic cell).

[0209] "Active immune response" or "active immunity" is characterized by "the involvement of host tissues and cells after encounter with an immunogen. It involves the differentiation and proliferation of immunocompetent cells in the lymphoreticular tissue, leading to antibody synthesis or the development of cell-mediated reactivity, or both." Herbert B. Herscowitz, Immunophysiology: Cell Function and Cellular Interactions in Antibody Formation, in IMMUNOLOGY: BASIC PROCESSES 117 (Joseph A. Bellantied., 1985). In other words, the host mounts an active immune response after being exposed to an immunogen through infection or vaccination. Active immunity can be contrasted with passive immunity, which is obtained by "transferring preformed substances (antibodies, transfer factors, thymic grafts, interleukin-2) from an actively immunized host to a non-immune host." Id.

[0210] As used herein, a "protective" immune response or "protective" immunity indicates that the immune response confers some benefit to the subject because it prevents or reduces the incidence of disease. Alternatively, a protective immune response or protective immunity can be used to treat and / or prevent disease, particularly cancer or tumors (e.g., by preventing cancer or tumor formation, by causing cancer or tumor regression and / or by preventing metastasis and / or by preventing the growth of metastatic nodules). The protective effect can be complete or partial, as long as the benefits of the treatment outweigh any disadvantages.

[0211] In certain embodiments, viral vectors or cells comprising heterologous nucleic acid can be administered in an immunogenic effective amount, as described below.

[0212] By administering a viral vector expressing one or more cancer cell antigens (or immunologically similar molecules) or any other immunogen that produces an immune response against cancer cells, the viral vector of the present disclosure can also be administered for cancer immunotherapy. For illustration, an immune response can be generated by administering a viral vector comprising a heterologous nucleic acid encoding a cancer cell antigen for a cancer cell antigen in a subject, for example to treat a patient with cancer and / or to prevent cancer from developing in a subject. As described herein, a viral vector can be administered to a subject in vivo or by using an ex vivo method. Alternatively, a cancer antigen can be expressed as a part of a viral capsid or otherwise associated with a viral capsid (e.g., as described above).

[0213] As another alternative, any other therapeutic nucleic acid (eg, RNAi) or polypeptide (eg, cytokine) known in the art can be administered to treat and / or prevent cancer.

[0214] As used herein, the term "cancer" encompasses neoplastic cancers. Likewise, the term "cancer tissue" encompasses tumors. "Cancer cell antigens" encompass tumor antigens.

[0215] The term "cancer" has its understood meaning in the art, e.g., uncontrolled growth of tissue with the potential to spread to distant parts of the body (i.e., metastasis). Exemplary cancers include, but are not limited to, melanoma, adenocarcinoma, thymoma, lymphoma (e.g., non-Hodgkin's lymphoma, Hodgkin's lymphoma), sarcoma, lung cancer, liver cancer, colon cancer, leukemia, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer, brain cancer, and any other cancer or malignant condition now known or later determined. In representative embodiments, the present disclosure provides methods for treating and / or preventing neoplastic cancer.

[0216] The term "tumor" is also understood in the art, for example, as an abnormal mass of undifferentiated cells within a multicellular organism. Tumors can be malignant or benign. In representative embodiments, the methods disclosed herein are used to prevent and treat malignant tumors.

[0217] By the terms "treating cancer", "treatment of cancer" and equivalent terms, it is intended to reduce or at least partially eliminate the severity of cancer, and / or slow and / or control the progression of the disease, and / or stabilize the disease. In specific embodiments, these terms indicate preventing or reducing or at least partially eliminating the metastasis of cancer, and / or preventing or reducing or at least partially eliminating the growth of metastatic nodules.

[0218] By the term "preventing cancer" or "prevention of cancer" and equivalent terms, it is intended that the method at least partially eliminates or reduces and / or delays the incidence and / or severity of the onset of cancer. In other words, the onset of cancer in a subject may be reduced and / or delayed in likelihood or probability.

[0219] In a specific embodiment, cells can be taken from a subject with cancer and contacted with a viral vector expressing a cancer cell antigen according to the present disclosure. The modified cells are then administered to the subject, thereby inducing an immune response against the cancer cell antigen. This method can be advantageously used in immunocompromised subjects who are unable to initiate a sufficient immune response in vivo (i.e., unable to produce sufficient amounts of enhanced antibodies).

[0220] It is known in the art that immune responses can be enhanced by immunomodulatory cytokines (e.g., α-interferon, β-interferon, γ-interferon, ω-interferon, τ-interferon, interleukin-1α, interleukin-1β, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-18, B cell growth factor, CD40 ligand, tumor necrosis factor-α, tumor necrosis factor-β, monocyte chemoattractant protein-1, granulocyte-macrophage colony stimulating factor and lymphotoxin). Therefore, immunomodulatory cytokines (preferably, CTL inducing cytokines) can be administered to a subject together with a viral vector.

[0221] The cytokines may be administered by any method known in the art. Exogenous cytokines may be administered to the subject, or alternatively, nucleic acids encoding the cytokines may be delivered to the subject using a suitable vector and the cytokines produced in vivo.

[0222] Subjects, drug formulations and modes of administration

[0223] The viral vectors and capsids according to the present invention can be used for veterinary and medical applications. Suitable subjects include birds and mammals. The term "birds" as used herein includes, but is not limited to, chickens, ducks, geese, quails, turkeys, pheasants, parrots, parakeets, etc. The term "mammals" as used herein includes, but is not limited to, humans, non-human primates, cattle, sheep, goats, horses, cats, dogs, rabbits, etc. Human subjects include neonates, infants, adolescents, adults, and elderly subjects.

[0224] In representative embodiments, a subject is "in need of" the methods of the disclosure.

[0225] In a specific embodiment, the present disclosure provides a pharmaceutical composition comprising a viral vector and / or capsid of the present disclosure in a pharmaceutically acceptable carrier, and optionally other medical agents, medicaments, stabilizers, buffers, carriers, adjuvants, diluents, etc. For injection, the carrier is generally a liquid. For other methods of administration, the carrier can be solid or liquid. For inhalation administration, the carrier will be inhalable and optionally can be in the form of solid or liquid particles.

[0226] "Pharmaceutically acceptable" refers to a substance that is not toxic or otherwise undesirable, ie, the substance can be administered to a subject without causing any undesirable biological effect.

[0227] One aspect of the present disclosure is a method for transferring nucleic acids to cells in vitro. Viral vectors can be introduced into cells at an appropriate multiplicity of infection according to standard transduction methods suitable for specific target cells. The titer of the viral vector administered can vary depending on the type and number of target cells and the specific viral vector, and can be determined by those skilled in the art without undue experimentation. In a representative embodiment, at least about 10 3 infectious units, optionally at least about 10 5 infectious units into cells.

[0228] The cell introduced into the viral vector can be any type, including but not limited to neural cells (including cells of the peripheral and central nervous systems, particularly brain cells such as neurons and oligodendrocytes), lung cells, eye cells (including retinal cells, retinal pigment epithelial cells and corneal cells), epithelial cells (such as intestinal and respiratory epithelial cells), muscle cells (such as skeletal muscle cells, cardiomyocytes, smooth muscle cells and / or diaphragm cells), dendritic cells, pancreatic cells (including islet cells), hepatocytes, cardiomyocytes, osteocytes (such as bone marrow stem cells), hematopoietic stem cells, spleen cells, keratinocytes, fibroblasts, endothelial cells, prostate cells, reproductive cells, etc. In representative embodiments, the cell can be any progenitor cell. As another possibility, the cell can be a stem cell (e.g., neural stem cell, liver stem cell). As another alternative, the cell can be a cancer or tumor cell. In addition, as noted above, the cell can be from any kind of source.

[0229] The viral vector can be introduced into the cell in vitro for the purpose of applying the modified cell to the subject. In a specific embodiment, the cell has been taken out from the subject, the viral vector is introduced therein, and the cell is then applied back to the subject again. The cell is taken out from the subject for in vitro operation, and the method of then introducing the subject back is known in the art (see, for example, U.S. Patent No. 5,399,346). Alternatively, the recombinant viral vector can be introduced into the cell from the donor subject, into the cultured cell, or into the cell from any other suitable source, and the cell is applied to the subject (i.e., "receptor" subject) in need thereof.

[0230] Suitable cells for ex vivo nucleic acid delivery are described above. The dosage of cells administered to a subject will vary depending on the age, condition and species of the subject, the cell type, the nucleic acid expressed by the cell, the mode of administration, etc. Typically, at least about 10 μg of the cell is administered per dose in a pharmaceutically acceptable carrier. 2 to about 10 8 cells or at least about 10 3 to about 10 6In a specific embodiment, the cells transduced with the viral vector are administered to a subject in a therapeutically effective amount or a prophylactically effective amount together with a pharmaceutical carrier.

[0231] In some embodiments, the viral vector is introduced into the cell, and the cell is administered to the subject to induce an immunogenic response to the delivered polypeptide (e.g., expressed as a transgenic or expressed in a capsid). Typically, a certain amount of cells expressing an immunogenic effective amount of polypeptide are used in combination with a pharmaceutically acceptable carrier. "Immunogenic effective amount" is the amount of expressed polypeptide, which is sufficient to cause an active immune response to the polypeptide in a subject to which a pharmaceutical preparation is administered. In a specific embodiment, the dosage is sufficient to produce a protective immune response (as defined above). The degree of protection conferred does not need to be complete or permanent, as long as the benefits of administering the immunogenic polypeptide outweigh any of its shortcomings.

[0232] Another aspect of the present disclosure is a method of administering the viral vector and / or viral capsid to a subject. The viral vector and / or capsid according to the present invention can be administered to a human subject or animal in need thereof by any method known in the art. Optionally, the viral vector and / or capsid are delivered in a pharmaceutically acceptable carrier at a therapeutically effective dose or a prophylactically effective dose.

[0233] The viral vectors and / or capsids of the present disclosure may be further administered to elicit an immunogenic response (e.g., as a vaccine). Typically, the immunogenic compositions of the present disclosure comprise an immunogenic effective amount of viral vectors and / or capsids in combination with a pharmaceutically acceptable carrier. Optionally, the dosage is sufficient to produce a protective immune response (as defined above). The degree of protection conferred need not be complete or permanent, as long as the benefits of administering the immunogenic polypeptide outweigh any of its disadvantages. The subject and immunogen are as described above.

[0234] The dosage of the viral vector and / or capsid to be administered to a subject depends on the mode of administration, the disease or condition to be treated and / or prevented, the condition of the individual subject, the particular viral vector or capsid, and the nucleic acid to be delivered, etc., and can be determined in a routine manner. An exemplary dosage for achieving a therapeutic effect is at least about 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 The titer of transduction units is about 10 8 -10 13 The titer of transducing units.

[0235] In certain embodiments, more than one administration (eg, two, three, four or more administrations) may be employed to achieve desired gene expression levels at various intervals (eg, daily, weekly, monthly, yearly, etc.).

[0236] Exemplary modes of administration include oral, rectal, transmucous, intranasal, inhalation (e.g., by aerosol), oral (e.g., sublingual), vaginal, intrathecal, intraocular, transdermal, intrauterine (or intraovo), parenteral (e.g., intravenous, subcutaneous, intradermal, intramuscular, intradermal, intrapleural, intracerebral and intraarticular), topical (e.g., to skin and mucosal surfaces, including airway surfaces and transdermal administration), intralymphatic, etc., and direct tissue or organ injection (e.g., to liver, skeletal muscle, myocardium, diaphragm or brain). In some embodiments, intramuscular includes administration to skeletal muscle, diaphragm and / or myocardium. Administration can also be administration to a tumor (e.g., in or near a tumor or lymph node). In any given case, the most appropriate route will depend on the nature and severity of the condition being treated and / or prevented and the nature of the specific carrier used.

[0237] Delivery to the target tissue can also be achieved by delivering a depot comprising a viral vector and / or capsid. In representative embodiments, the depot comprising a viral vector and / or capsid is implanted in skeletal muscle, myocardial and / or diaphragmatic tissue, or the tissue may be contacted with a membrane or other matrix comprising a viral vector and / or capsid. Such implantable substrates or substrates are described in U.S. Patent No. 7,201,898.

[0238] In specific embodiments, the viral vectors and / or viral capsids according to the invention are administered to skeletal muscle, diaphragm and / or myocardium (e.g., to treat and / or prevent muscular dystrophy, heart disease). In some embodiments, the viral vectors and / or viral capsids according to the invention are administered to treat PAD or congestive heart failure.

[0239] The methods of the disclosure can also be practiced to generate antisense RNA, RNAi, or other functional RNA (eg, ribozymes) for systemic delivery.

[0240] Injections can be prepared in conventional forms, can be liquid solutions or suspensions, solid forms suitable for dissolving or suspending in liquids before injection, or emulsions. Alternatively, viral vectors and / or viral capsids of the present disclosure can be administered in a local rather than systemic manner, for example, in a reservoir or a sustained-release formulation. In addition, viral vectors and / or viral capsids can be attached to an implantable matrix for delivery (for example, as described in U.S. Patent Publication No. US-2004-0013645-A1).

[0241] Viral vectors and viral capsids can be administered to tissues of the CNS (eg, brain, eye) and can advantageously result in a more widespread distribution of the viral vector or capsid than would be observed in the absence of the present disclosure.

[0242] In specific embodiments, the delivery vehicles of the present disclosure can be administered to treat diseases of the CNS, including genetic diseases, neurodegenerative diseases, psychiatric disorders, and tumors.

[0243] Exemplary diseases of the CNS include, but are not limited to, Alzheimer's disease, Parkinson's disease, Huntington's disease, Canavan disease, Leigh's disease, Refsum's disease, Tourette syndrome, primary lateral sclerosis, amyotrophic lateral sclerosis (ALS), progressive muscular dystrophy, Pick's disease, muscular dystrophy, multiple sclerosis, myasthenia gravis, Binswanger's disease, trauma resulting from spinal cord injury and / or head injury (e.g., traumatic brain injury), Tay-Sachs disease, Lesch-Nyan disease, and disease), epilepsy, stroke, cerebral infarction, psychiatric disorders including mood disorders (e.g., depression, bipolar disorder, persistent affective disorder, secondary mood disorder), schizophrenia, drug dependence (e.g., alcoholism and other substance dependence), neurological disorders (e.g., anxiety, obsessive-compulsive disorder, somatoform disorder, dissociative disorder, grief, postpartum depression), psychosis (e.g., hallucinations and delusions), dementia, delusions, attention deficit disorder, psychosexual disorders, any neurodegenerative disease that may benefit from or require axon / neuron regeneration and / or repair, cognitive disorders, behavioral disorders, sleep disorders, pain disorders, eating or weight disorders (e.g., obesity, cachexia, anorexia nervosa and bulimia) and cancers and tumors of the CNS (e.g., pituitary tumors).

[0244] Disorders of the CNS include ophthalmic disorders involving the retina, posterior tract, and optic nerve (eg, retinitis pigmentosa, diabetic retinopathy and other retinal degenerative diseases, uveitis, age-related macular degeneration, glaucoma).

[0245] Most, if not all, ophthalmic diseases and disorders are associated with one or more of three indications: (1) angiogenesis, (2) inflammation, and (3) degeneration. The delivery vehicles of the present invention can be used to deliver anti-angiogenic factors; anti-inflammatory factors; factors that delay cell degeneration, promote cell sparing, or promote cell growth, and combinations of the foregoing.

[0246] For example, diabetic retinopathy is characterized by angiogenesis. Diabetic retinopathy can be treated by delivering one or more anti-angiogenic factors intraocularly (e.g., in the vitreous body) or periocularly (e.g., in the sub-Tenon's fascia region). One or more neurotrophic factors can also be delivered intraocularly (e.g., in the vitreous body) or periocularly.

[0247] Uveitis involves inflammation. One or more anti-inflammatory factors can be administered by intraocular (eg, vitreous or anterior chamber) administration of the delivery vehicles of the present disclosure.

[0248] In contrast, retinitis pigmentosa is characterized by retinal degeneration.In representative embodiments, retinitis pigmentosa can be treated by intraocular administration (eg, intravitreal administration) of a delivery vector encoding one or more neurotrophic factors.

[0249] Age-related macular degeneration involves angiogenesis and retinal degeneration. The disease can be treated by intraocular (e.g., vitreous) administration of a delivery vector encoding one or more neurotrophic factors of the invention and / or intraocular or periocular (e.g., in the sub-Tenon's fascia region) administration of a delivery vector encoding one or more anti-angiogenic factors of the invention.

[0250] Glaucoma is characterized by increased intraocular pressure and loss of retinal ganglion cells. Treatment of glaucoma includes administration of one or more neuroprotectants that protect cells from excitotoxic damage using the delivery vehicle of the present invention. These agents include intraocular delivery, optionally intraocularly delivered N-methyl-D-aspartate (NMDA) antagonists, cytokines and neurotrophic factors.

[0251] In other embodiments, the present disclosure can be used to treat epileptic seizures, for example, to reduce the onset, incidence or severity of epileptic seizures. The efficacy of therapeutic treatments for epileptic seizures can be assessed by behavioral (e.g., shaking of the eyes or mouth, ticks) and / or electrographic means (most epileptic seizures have characteristic electrographic abnormalities). Thus, the present invention can also be used to treat epilepsy, which is characterized by multiple epileptic seizures over time.

[0252] In a representative embodiment, somatostatin (or its active fragment) is administered to the brain to treat pituitary tumors using a delivery vector disclosed herein. According to this embodiment, a delivery vector encoding somatostatin (or its active fragment) is administered to the pituitary by microinfusion. Similarly, this treatment can be used to treat acromegaly (abnormal growth hormone secretion of the pituitary). Somatostatin nucleic acid (e.g., GenBank accession number J00306) and amino acid (e.g., GenBank accession number P01166; containing processed active peptides somatostatin-28 and somatostatin-14) sequences are known in the art.

[0253] In certain embodiments, the vector may comprise a secretion signal, as described in US Pat. No. 7,071,172.

[0254] In representative embodiments of the present disclosure, viral vectors and / or viral capsids are administered to the CNS (e.g., administered to the brain or eyes). Viral vectors and / or capsids can be introduced into the spinal cord, brainstem (medulla oblongata, pons), midbrain (hypothalamus, thalamus, epithalamus, pituitary gland, substantia nigra, pineal gland), cerebellum, telencephalon (striatum, cerebrum including occipital lobe, temporal lobe, parietal lobe and frontal lobe, cortex, basal ganglia, hippocampus and portal vein tongue (portaamygdala), limbic system, neocortex, striatum, cerebrum and hypothalamus. Viral vectors and / or capsids can also be administered to different areas of the eye, such as the retina, cornea and / or optic nerve.

[0255] The viral vector and / or capsid can be delivered into the cerebrospinal fluid (e.g., by lumbar puncture) for more dispersed administration of the delivery vector. The viral vector and / or capsid can be further administered intravascularly to the CNS in the case where the blood-brain barrier is disturbed (e.g., brain tumor or cerebral infarction).

[0256] The viral vectors and / or capsids can be administered to the desired area of ​​the CNS by any route known in the art, including, but not limited to, intracerebroventricular, intracisternal, intraparenchymal, intracranial, intrathecal, intraocular, intracerebral, intraventricular, intravenous (e.g., in the presence of a sugar such as mannitol), intranasal, intraauricular, intraocular (e.g., intravitreal, subretinal, anterior chamber), and periocular (e.g., subTenon's) delivery as well as intramuscular delivery with retrograde delivery to motor neurons.

[0257] In a specific embodiment, the viral vector and / or capsid are administered to the desired area or compartment in the CNS in a liquid formulation by direct injection (e.g., stereotactic injection). In other embodiments, the viral vector and / or capsid can be provided to the desired area by topical application or provided by intranasal administration of an aerosol formulation. Administration to the eye can be by topical application of droplets. As another alternative, the viral vector and / or capsid can be administered as a solid sustained release formulation (see, e.g., U.S. Patent No. 7,201,898).

[0258] In additional embodiments, viral vectors can be used for retrograde transport to treat and / or prevent diseases and disorders involving motor neurons (e.g., amyotrophic lateral sclerosis (ALS); spinal muscular atrophy (SMA), etc.). For example, a viral vector can be delivered to muscle tissue, from which it can migrate into neurons.

[0259] The following examples are for illustrative purposes only and are not intended to be limiting. Example

[0260] Example 1 Discovery of a neurotropic footprint that enables AAV transport across the blood-brain barrier

[0261] Adeno-associated virus (AAV) is a non-pathogenic parvovirus, consisting of a small 25nm icosahedral capsid, packaging about 4.7kb single-stranded DNA genome. A variety of AAV capsid sequences have been isolated from human and primate tissues, which have been classified into several different clades based on sequence and structural diversity. Throughout these clades, different serotypes show a wide range of tropisms at the species, tissue and cell levels. These different phenotypes are determined by the capsid structure. The AAV capsid is assembled from 60 viral protein (VP) subunits. The core VP monomer (VP3) has a jelly roll β barrel structure consisting of 7 antiparallel β chains connected by a cross loop region. The parts of these highly variable loops are surface exposed and define the topological structure of the AAV capsid, which in turn determines the tissue tropism, antigenicity and receptor use of various AAV serotypes. The surface loop residues on the AAV capsid are highly plastic and easy to modify, thereby providing control of antigenicity, transduction spectrum and tissue tropism.

[0262] The first step in the AAV life cycle is recognition and attachment to cell surface glycan receptors. These include heparan sulfate (HS) for AAV2, AAV3, and AAV6, α2,3- and α2,6-N-linked sialic acid (Sia) for AAV1, AAV5, and AAV6, O-linked sialic acid for AAV4, and galactose (Gal) for AAV9. Following glycan binding, cellular uptake of AAV involves secondary co-receptors, including various growth factor receptors as well as integrins. Recently, the transmembrane protein KIAA0319L (AAVR) has been identified as a universal receptor for multiple AAV serotypes. These factors, together with tissue glycosylation patterns, contribute to the different tissue tropisms of different AAV serotypes. With regard to the CNS in particular, different AAV serotypes display a range of transduction profiles and cell tropisms depending on the route of administration. For example, when administered directly into the mouse CNS by direct intraparenchymal or intracerebrospinal fluid (CSF) injection, AAV capsids undergo axonal transport and transsynaptic spread in the anterograde and / or retrograde directions, depending on the serotype. In addition, we have recently demonstrated that glial-associated lymphatic (glymphatic) transport of the CSF affects the spread of AAV within the mouse brain parenchyma and clearance from the CNS.

[0263] In order to achieve CNS gene transfer, the intravenously administered AAV vector must first pass through the blood-brain barrier (BBB) ​​to enter the brain. Composed of endothelial cell tight junctions with associated astrocyte end feet and adventitial cells, the BBB blocks the diffusion and paracellular flow of macromolecules / particles and regulates the transport of other molecules. Most viruses that infect the brain are achieved by destroying or weakening the BBB. However, some viruses have designed strategies to achieve entry into the CNS by methods such as the following: hitchhiking (such as HIV) in host immune cells, by infecting brain endothelial cells or by infecting peripheral nerves and utilizing axonal transport (such as rabies). In the case of AAV, the BBB prevents most serotypes from entering the brain, but there are a few notable exceptions. For example, intravascular administration of AAV serotypes 1-6 and 8 results in poor CNS transduction, and in other serotypes, isolates AAV9, AAVrh.8 and AAVrh.10 have been shown to effectively pass through the BBB in different animal models.

[0264] To achieve therapeutic levels of transgene expression in the CNS, high vector doses are often required (e.g., 1 × 10 14 vg / kg). In addition to the burdens associated with scale-up and cost, high vector doses have been shown to cause adverse side effects, such as hepatotoxicity. To improve the specificity / efficiency of gene transfer to the CNS and reduce the effective vector dose, a better understanding of the structural features that enable AAV capsids to penetrate the BBB is needed.

[0265] To dissect the structure-function relevance of crossing the BBB, we generated combinatorial libraries of variant capsid genes using only two serotypes—AAV1, which does not cross the vasculature, and AAVrh.10, which is known to cross the BBB efficiently. Rather than evolving new variants, we selected individual variants for further screening in mice through computational, phylogenetic, and structural analyses.

[0266] Generation of chimeric AAV capsid plates

[0267] AAV1 / rh.10 domain-swapped capsid library was generated by DNA shuffling. Briefly, the Cap genes of AAV1 and AAVrh.10 were randomly fragmented by brief DNase digestion and reassembled using primer-free PCR using Phusion High-Fidelity DNA polymerase (NEB Cat#M0530L), where partial homology of short (<400 bp) fragments allowed self-priming of the fragments. A secondary PCR step was then used to amplify the reassembled full-length Cap sequence library using specific conservative primers flanking the Cap gene, while flanking restriction sites were inserted to facilitate subsequent cloning into the pTR plasmid backbone for viral production.

[0268] Phylogeny and sequence analysis

[0269] The amino acid sequences of different AAV capsid isolates were aligned using ClustalW, and phylogenetic trees were generated using the MEGAv7.0.21 software package. Phylogeny was generated using the neighbor-joining algorithm, and amino acid distances were calculated using Poisson correction. Statistical tests were performed by bootstrapping of 1000 replicates to test the confidence of phylogenetic analysis and generate a self-referenced consensus tree. Branches corresponding to partitions that were reproduced in less than 50% of the self-referenced replicates were collapsed. The percentage of replicate trees is displayed next to the branches, where the associated taxa are clustered together in the self-reference test. All sequence alignments were performed using Invitrogen's Vector NTI Advance 11.5.2 software.

[0270] Virus production and titer

[0271] An updated triple plasmid transfection protocol was used to generate recombinant AAV vectors. Specifically, the transfected plasmids included (i) a capsid-specific pXR helper plasmid (i.e., pXR1, pXRrh.10, or various plasmids encoding various chimeric Cap genes used in this study), (ii) an adenoviral helper plasmid pXX680, and (iii) pTR-CBh-scGFP or pTR-CBA-Luc plasmids encoding a self-complementary green fluorescent protein (GFP) reporter transgene driven by a chicken β-actin hybrid (CBh) promoter or a luciferase reporter transgene (Luc) driven by a chicken β-actin promoter (CBA), respectively, flanked by inverted terminal repeats (TR) derived from the AAV2 genome. Viral vectors were purified using iodixanol density gradient ultracentrifugation. The vectors packaging the CBh-scGFP transgene were then buffer exchanged and concentrated using a Sartorius Vivaspin2 100 kDa molecular weight cutoff (MWCO) spin column (F-2731-100 Bioexpress, Kaysville, UT). The vectors packaging the CBA-Luc transgene were buffer exchanged and desalted using Zeba Spin Desalting Columns, 40K MWCO (Thermo Scientific, Cat#87770). After purification, viral genome titers were determined by quantitative PCR using Roche Lightcycler 480 (Roche Applied Sciences, Pleasanton, CA). Quantitative PCR primers were designed to specifically recognize the AAV2 reverse terminal repeat sequence (forward, 5'-AACATGCTACGCAGAGAGGGAGTGG–3'; (SEQ ID NO: 36), reverse, 5'-CATGAGACAAGGAACCCCTAGTGATGGAG-3') (SEQ ID NO: 37) (IDT Technologies, AmesIA).

[0272] Animal studies

[0273] All animal experiments were performed using 6- to 8-week-old female C57 / BL6 mice purchased from Jackson Laboratories (BAR Harbor, ME). These mice were maintained and treated in accordance with NIH guidelines and approved by the UNC Institutional Animal Care and Use Committee (IACUC). To investigate the ability of AAV vectors to cross the BBB and transduce CNS cell populations, 5 × 10 11vg dose, AAV vectors packaging CBh-scGFP transgene or 1xPBS (treated as a mock) were administered intravenously (iv) by tail vein injection. To determine GFP reporter gene transgene expression, animals were sacrificed 21 days after injection with Avertin (0.2 ml of 1.25% solution) and then perfused transcardially with 30 ml of 1xPBS and subsequent 30 ml of 4% paraformaldehyde in PBS. Tissues including brain, heart, and liver were removed and after fixation for 24 hours, 50 μm thick sections of each tissue were obtained using a Leica VT 1200S vibrating blade microtome (Leica Biosystems, IL). Mouse brain sections were then immunostained as described below. For in vivo luciferase transduction and viral genome biodistribution experiments, 1×10 11 The mice were injected with 1x PBS or a viral vector packaging the CBA-luciferase transgene at a dose of 100 mg / mL. As described above, the mice were killed 14 days after injection and various tissues were removed. For these experiments, the tissues were dissected and frozen at -80°C before use instead of fixation with 4% paraformaldehyde in 1x PBS.

[0274] To quantify luciferase expression, mice were sacrificed 14 days after injection with 1 × 10 11 The mice with the viral genome of the CBA-Luc transgene were packaged, and the tissues were harvested and frozen at -80 ° C. Before mechanical lysis using Tissue Lyser II 352 instrument (Qiagen, Valencia, CA), the tissues were subsequently thawed, weighed, and lysed by adding 150 μl of 2x passive lysis buffer (Promega, Madison WI), and then centrifuged to remove any remaining tissue fragments. In order to measure luciferase transgenic expression, 50 μl supernatant from each lysate was then loaded onto the assay plate together with 50 μl of luciferin, and luminescence analysis was performed using a Victor2 luminometer (PerkinElmer, Waltham, MA). The relative light units obtained for each sample were then normalized to the input tissue weight of each sample, measured in grams. Data were plotted, and statistical analysis was performed using unpaired two-tailed T tests, Welch corrections, and ANOVA, followed by Tukey's multiple comparison tests where indicated. These statistical analyses were performed in GraphPad Prism Performed in software.

[0275] Tissue processing and histological analysis

[0276] For mouse experiments using viruses packaging a GFP reporter transgene, free-floating 50-μm thick coronal brain sections were stained in 24-well plates. The sections were incubated in a blocking buffer containing 10% goat serum and 1% Triton X (Sigma-Aldrich) in 1x PBS for 1 hour at room temperature. The sections were then incubated overnight at 4°C with a primary monoclonal rabbit α-GFP antibody (Life-Technologies-G10,362 1:750) diluted in blocking buffer. The next day, three 10-minute washes were performed with 1x PBS. Subsequent histochemical analysis of GFP expression was performed using the Vectastain ABC kit (Rabbit IgG PK-4001 kit, Vector biolabs, Burlingame, CA), and the tissues were mounted on microscope slides. Immunostained sections were digitally imaged in bright field (20x objective) by the UNC Translational Pathology Laboratory using an Aperio ScanScope XT instrument (Aperio Technologies, Vista, CA), and images were obtained using Leica eSlide Manager (centralized image storage and data management software) and analyzed using Aperio ImageScope and WebViewer software. Quantification was calculated by counting the number of morphologically determined GFP+ neurons or glial cells per 50 μm coronal brain section. Data were plotted and statistically analyzed as described above. Specific brain regions were identified based on comparisons with coronal mouse brain references obtained from the Allen Mouse Brain Atlas. To determine GFP expression in the heart and liver, tissues were stained for GFP with an anti-GFP primary antibody as described above; however, an anti-rabbit goat antibody conjugated to Alexa-488 was used as a secondary antibody at a dilution of 1:500 (anti-rabbit Abcam-96,883). Immunostained GFP in these tissues was then imaged using an EVOS FL epifluorescence cell imaging system (AMC / Life Technologies) using a GFP light cube (excitation 470 nm, emission 510 nm). Statistical analysis was performed as previously described.

[0277] Vector genome biodistribution

[0278] Animal studies were performed as described above. 21 days after injection, mice were killed and tissues were frozen at -80 ° C. Tissues were subsequently thawed and viral genomes were extracted from tissue lysates using DNeasy kits (Qiagen, Valencia, CA). Then, the viral genome copy number of each tissue was determined using quantitative PCR using primers specific for the luciferase transgene (forward, 5′-AAAAGCACTCTGATTGACAAATAC-3′ (SEQ ID NO: 38); and reverse, 5′-CCTTCGCTTCAAAAAATGGAAC-3′ (SEQ ID NO: 39)). Then, primers (forward, 5′-GGACCCAAGGACTACCTCAAGGG-3′ (SEQ ID NO: 40); and reverse, 5′-AGGGCACCTCCATCTCGGAAAC-3′ (SEQ ID NO: 41)) were used to normalize these viral genome copy numbers to the mouse lamin B2 housekeeping gene. The biodistribution of the viral genome is expressed as the ratio of the vector genome of each cell recovered for each tissue. Data were plotted and statistical analyses were performed as described previously.

[0279] Molecular modeling

[0280] Previously published coordinates (PDB ID, 3NG9) were used to generate the three-dimensional structure of the AAV1 VP3 trimer / three-fold symmetry axis. Homology models of AAVrh.10 and various AAV1 / rh.10 chimeric capsid structures were obtained using the SWISS-Model server (swissmodel.expasy.org), with the crystal structure of AAV8VP3 (PDB ID, 2QA0) used as a template, and structure-based alignments were generated using the Secondary Structure Matching (SSM) application in WinCoot software, with the AAV1 VP3 (PDB ID3NG9) monomer used as a template. The VP3 trimer / 3-fold symmetry axis, VP3 trimer dimer / 2-fold symmetry axis, VP3 pentamer / 5-fold symmetry axis, and complete capsid were generated using the VIPERd oligomer generator utility (viperdb.scripps.edu / oligomer_multi.php). PyMOL (PyMOL Molecular Graphics System, LLC, www.pymol.org). Stereoscopic roadmap projections of the AAV1RX capsid surface highlighting AAVrh.10-derived surface-exposed amino acid residues within the neural footprint were generated using RIVEM (Radial Interpretation of Viral Electron Density Maps) software.

[0281] Generation of AAV1 / rh.10 domain-swap libraries and isolation of chimeric capsid variants

[0282] We performed a comparative analysis of different capsid domains to determine the structure-function relevance for crossing the BBB. We generated an AAV1 / rh.10 domain-swap library by DNA shuffling. We chose AAV1 and AAVrh.10 as parental capsid sequences for DNA shuffling because of their clearly different abilities to cross the BBB and because of the shared sequence homology (85%) of their capsid (Cap) genes. Thirty-six chimeric capsid sequence clones were then isolated and sequenced. The variants generated from this library showed significant diversity at both the DNA and amino acid levels. Sequence alignment revealed continuous domain swaps, which we then organized in order of increasing homology from AAV1 to AAVrh.10 ( Figure 4 A, from top to bottom). The clonal groups were further phylogenetically characterized by constructing neighbor-joining trees that broadly classified these variants as more AAV1-like (clade A) or more AAVrh.10-like (clade E) ( Figure 4 B). Small-scale vector production was then used to establish relative titers to exclude capsids that were defective in assembly or packaging from the study. Homology-based structural models of parental and representative chimeric capsid trimers highlighting key surface domains / residues on the three-fold symmetry axis were generated ( Figure 4 C) to further narrow the list of chimeric capsid variants for initial in vivo screening. Ten chimeric capsid variants were selected based on structural analysis, of which six produced recombinant vectors (which packaged scGFP or ssLuc transgene cassettes) with titers similar to the parental AAV1 and AAVrh.10 vectors. These variants were then further screened.

[0283] In vivo screening identifies two AAV1 / rh.10 chimeric capsids capable of crossing the BBB following intravenous administration in adult mice

[0284] We then tested whether the selected groups of capsid variants differed in their ability to cross the BBB and transduce the CNS after IV administration. Notably, our approach did not involve directed evolution, as this strategy is generally applicable to the selection of optimal capsids and is less suitable for studying structure-function relationships. We injected 5 × 10 per mouse of AAV1, AAVrh.10, or one of six different chimeric AAV vectors via tail vein injection. 11 The chimeric AAV vector was packaged with a self-complementary CBh-GFP reporter cassette and injected into 6-8 week old mice at a dose of 100 viral genomes (vg).

[0285] GFP-positive neurons in the cerebral cortex were manually counted, quantified, and averaged across multiple coronal brain sections per mouse. For AAV1, n=2; for AAV1R6 and AAV1R7, n=3 ( Figure 1). Immunostaining of coronal brain sections 3 weeks after injection revealed that AAV1 transduction in the cerebral cortex was restricted to the vasculature, whereas AAVrh.10 showed robust transduction of a variety of cell populations, including neurons, glia, and endothelial cells, as determined morphologically ( Figure 2 , Figure 5 ). Further morphological evaluation of GFP+ cells indicated different phenotypes of the chimeric variants. AAV1R19.1 and AAV1R20 predominantly transduced microvascular endothelial cells in the cortex, whereas low to moderate transduction of neurons and glial cells was evident for AAV1R8 and AAV1R19d vectors ( Figure 5 ). In contrast, AAV1R6 and AAV1R7 showed robust transduction of cortical neurons, moderate transduction of glia, and sparse (if any) transduction of intracortical vascular structures. Representative images of the somatosensory areas of the cortex at high magnification are shown. Similar trends were consistently observed for these chimeras in other regions of the brain ( Figure 6 ). These observations suggest that the chimeric capsids AAV1R6 and AAV1R7 may have the ability to cross the BBB, similar to the parental AAVrh.10 vector, although the mechanism is unclear. However, unlike the parental AAV1 or AAVrh.10 vectors, none of the chimeras efficiently transduced the vasculature.

[0286] Intravenously delivered AAV1R6 and AAV1R7 chimeric capsids cross the BBB and preferentially transduce neurons throughout the brain.

[0287] We then further characterized the transduction profiles of these variants across multiple functionally relevant structures of the brain. For each brain region discussed below, representative images at higher magnification were obtained from GFP-immunostained mouse brain coronal sections and scanned in bright field at 20x magnification. Additionally, quantitative data for neuronal and glial transduction were determined for each region by counting GFP+ neurons and glial cells, respectively, based on cell morphology.

[0288] Cerebral cortex. AAVrh.10 showed robust transduction of neurons, glia, and vascular endothelial cells throughout the cortex, and in the case of intravascularly delivered AAV1, vascular transduction was observed, accompanied by an absence of neuronal expression and low expression levels in glia ( Figure 7 and Figure 8 We also observed that intravenously administered AAV1R6 and AAV1R7 (AAV1R6 / 7) vectors mediated robust GFP expression in cortical neurons and reduced expression in glia in the amygdala, piriform, entorhinal, temporal association, auditory, somatosensory, motor, posterior parietal, and posterior cortical regions throughout the cortex, but with a consistent trend across the analyzed sections. For the motor cortex ( Figure 7 A) and the somatosensory areas of the cortex ( Figure 7 B), shows representative images of transduced cortical areas. In addition, AAV1R6 / 7 appears to display preferential neuronal cell tropism throughout the cortex, showing moderate glial transduction and significantly reduced vascular transduction. This feature is in stark contrast to vasculotropic AAV1 and AAVrh.10, which transduce neurons, glia, and vascular endothelial cells with high efficiency ( Figure 7 A and 7B). Although AAV1R6 / 7 mediated robust neuronal and moderate glial expression throughout the cortex, their expression levels were still lower than those achieved with AAVrh. These trends were confirmed by quantitative morphological analysis of our GFP+ cells ( Figure 8 A and 8B), which show statistically significant differences in cortical transduction for AAVrh.10, AAV1R6, and AAV1R7 relative to AAV1. A final difference worth noting is that AAVrh.10 transduction across the cortex tends to be concentrated in the periphery of this tissue, around cortical layers 1-3, particularly within regions of the posterior cortex, motor, somatosensory, and visual cortices. While this could be attributed to differential immunostaining, we observed this phenomenon to be highly consistent across stained AAVrh.10 sections in our analysis. This trend did not apply to AAV1R6 / 7, which appeared to mediate a more evenly distributed expression throughout the cortical layers.

[0289] Hippocampus. Following intravenous delivery, the chimeric AAV1R6 / 7 vector appeared to mediate robust GFP expression in neurons throughout the hippocampus bilaterally across the cerebral hemispheres. GFP+ hippocampal neurons were observed within the CA1, CA2, and CA3 pyramidal layers ( Figure 7 C, CA2 and part of CA1 are shown). AAV1R6 / 7 also appears to effectively transduce neurons within the dentate gyrus, showing a large number of GFP+ neurons that appear to be granule cells based on morphology ( Figure 7 D). AAV1R6 / 7 displayed a neuronal transduction profile in the hippocampus similar to that seen with AAVrh.10. However, in contrast to AAVrh.10, AAV1R6 / 7 did not appear to transduce glial or endothelial cells in either region at any appreciable level, with no significant differences observed in GFP+ glial cells between AAV1 and AAV1R6 / 7 ( Figure 8 C and 8D).

[0290] AAV1 transduction observed in the hippocampus was again limited to the vasculature. Furthermore, these qualitative trends were observed in the hippocampus ( Figure 8 C) and dentate gyrus ( Figure 8Quantitative data of neuronal and glial cell transduction were confirmed in D).

[0291] Thalamus. For AAV1R6 / 7, GFP+ neurons were detected in the thalamus at levels comparable to AAVrh.10 ( Figure 7 E). In addition, AAV1R6 / 7 showed minimal transduction of the endothelium, as well as significantly reduced levels of glial transduction in the thalamus compared with AAVrh. Quantitative data further confirmed these trends ( Figure 8 E) In these quantitative data, it was found that the transduction of thalamic neurons by AAVrh.10, AAV1R6, and AAV1R7 was significantly different relative to AAV1. In contrast, no significant difference was found in the transduction of thalamic glia by AAV1R6 / 7 relative to AAV1.

[0292] Hypothalamus. Despite some variability, we observed consistent low-level GFP expression in the hypothalamus for both parental and chimeric vectors when administered systemically, regardless of cell type ( Figure 7 F). Variation in the level of neuronal transduction in the hypothalamus for AAVrh.10 was observed, revealing high and low numbers of GFP+ neurons in mice. This transduction profile is illustrated by the bias shown by AAVrh.10 transduction in our quantitative data ( Figure 8 F). AAV1 showed moderate hypothalamic transduction that was limited to the vasculature. AAV1R6 / 7 vectors showed low numbers of GFP+ neurons and glial cells, as well as a few GFP+ endothelial cells in the hypothalamus ( Figure 7 F and Figure 8 F).

[0293] Striatum. AAV1R6 / 7 is as efficient as AAVrh10 in transducing neurons in the striatum (particularly the caudate putamen) Figure 7 G), as further confirmed by our quantitative data, which showed significant differences for each relative to AAV1; however, these vectors transduced approximately 2-fold fewer glial cells and a lower number of endothelial cells in the striatum ( Figure 8 G), despite some observed changes.

[0294] Amygdala. The amygdala transduction profile for AAV1R6 / 7 showed strong neuronal GFP expression, which was significantly different from AAV1. A small number of GFP+ glial cells were detected, which was not significantly different from AAV1 ( Figure 7 H and Figure 8 H), similar to other brain regions such as the striatum and thalamus, almost no detectable GFP+ endothelial cells were observed.

[0295] In conclusion, morphological evaluation of immunostained brain regions from mice following intravenous delivery of AAV1R6 and AAV1R7 demonstrated robust and selective neuronal transduction comparable to that of the parental AAVrh.10. Furthermore, these chimeras showed reduced glial transduction, and their ability to transduce brain microvascular endothelial cells appeared diminished. Furthermore, these results appeared to be consistent across various brain regions, with the exception of the hypothalamus, where low transduction levels were generally observed.

[0296] Detargeting of AAV1R6 and AAV1R7 from the liver while retaining the parental cardiac transduction profile

[0297] We analyzed the relative cardiac and liver transduction of these variants compared to the parental serotype by immunostaining heart and liver sections. 11 Vg was packaged with a hybrid chicken β-actin promoter (CBh) (CBh-scGFP) vector (AAV1, AAV1R6 or AAV1R7) linked to a green fluorescent protein (GFP) coding sequence or PBS as a negative control and systemically administered to 6-8 week old female BL6 mice by tail vein injection. Mice were sacrificed 21 days after injection and tissues were harvested, fixed and sectioned. Microscopy was used to visualize GFP reporter gene transduction. GFP expression was quantified by averaging the relative fluorescence of multiple images per mouse using ImageJ software. For mock, n=1, for AAV1, n=2, for AAV1R6 and AAV1R7, n=3.

[0298] like Fig.10 As shown, both chimeric vectors exhibited comparable levels of GFP expression in the heart relative to the parental serotypes AAV1 and AAVrh.10, and no significant differences were found for AAVrh.10, AAV1R6, or AAV1R7 relative to AAV1; however, AAVrh.10 expression levels in cardiac tissue showed significant variation in mice ( Fig.10 A and 10B). In the liver, AAV1 showed moderate transduction levels, while AAVrh.10 performed exceptionally well, demonstrating higher log-fold transduction. In contrast, AAV1R6 and AAV1R7 mediated negligible GFP expression in the liver at background levels comparable to those in mock-treated mice ( Fig.10 B), which was significantly reduced relative to AAVrh. 10. We therefore concluded that AAV1R6 and AAV1R7 are liver detargeted relative to their parental serotypes.

[0299] Separately, an AAV vector packaging the chicken β-actin (CBA) promoter linked to the luciferase coding sequence to produce the CBA-luciferase transgene was placed at 1×10 11The dose of vg was administered to C57 / B16 mice by tail vein injection. Mice were sacrificed 14 days after injection, tissues were harvested, minced, lysed and subjected to luciferase assay to detect relative transduction levels in brain, heart, liver and spinal cord tissues. Data were normalized as relative light units per gram of tissue. In the brain, AAV1R6, AAV1R7 and AAV1RX showed considerable transduction levels, although not as high as AAVrh.10 ( Figure 3 ). The chimeric capsids additionally showed comparable transduction levels to the parental AAV1 and AAVrh.10 capsids in the heart. In the spinal cord, the transduction levels of the chimeras appeared intermediate between the parents. Strikingly, this data further demonstrates that AAV1R6, AAV1R7, and AAV1RX are all liver detargeted. N=3.

[0300] Structural analysis of the AAV1R6 chimeric capsid identified three potential domains of AAVrh.10 that may enable crossing the BBB

[0301] Sequence analysis showed that AAV1R6 has 97-98% identity with AAV1, with 18 unique amino acid residues derived from AAVrh.10. AAV1R7 is also largely identical to AAV1, but has a total of 22 residues derived from AAVrh.10, including 18 residues present in AAV1R6. Of the 4 additional residues unique to AAV1R7, two are located within the VP1 unique (VP1u) N-terminal region (189I, 206A), and the other two are located in the buried VP3 N-terminal region (224S and 225S). Because these residues are not exposed on the capsid surface, and because in vivo data indicate that the transduction profiles displayed by AAV1R6 and AAV1R7 are equivalent ( Figure 7 and Figure 8 ), so we excluded AAV1R7 from the rest of our analysis and focused only on AAV1R6.

[0302] AAV1R6 has three non-contiguous residues from the AAVrh.10 parent strain. The first group of residues (group i) includes three amino acids (148P, 152R, and 153S) in the VP1u region ( Fig. 9 A). Specifically, one residue is located near basic region 1 (BR1), which contains the first nuclear localization signal (NLS) of VP1. In addition, group i also contains two residues (158T and 163K) near the NLS located in the N-terminal region of VP2 ( Fig. 9 A) As mentioned before, these residues are not surface exposed but remain internalized within the capsid until subsequent trafficking pathways within the cell.

[0303] The second group of residues on AAV1R6 derived from AAVrh.10 (group ii) consists of 8 amino acids including the BC loop and is located within variable region I (VR-1) ( Fig. 9 A and 9B). These residues are exposed on the capsid surface at the base of the protrusions on the 3-fold symmetry axis ( Fig. 9 D and 9F), and also located in the depression at the 2-fold symmetry axis ( Fig. 9 C and 9F). It is also important to note that this set of amino acid residues on AAVrh.10 was replaced with AAV1 residues in the chimeric AAV1R8 / 19 / 20 capsid, which is unable to penetrate the CNS after systemic administration.

[0304] The third group of residues (group iii) present in AAV1R6 derived from AAVrh.10 includes a total of 6 amino acids. Four of these residues (328Q, 330E, 332T, and 333K) are located within the VR-II,DE loop, which contributes to the formation of the hole at the 5-fold symmetry axis ( Fig. 9 A, 9B, 9E, 9F). The last two remaining residues in this group (343I and 347T) are located in β-strand E, located inside the capsid ( Fig. 9 A and 9B). Although these residues differ between AAV1 and AAVrh.10, it should be noted that they are relatively conserved among different AAV serotypes.

[0305] Rational design of AAV1RX, a chimeric capsid with a minimal footprint from AAVrh.10 for crossing the BBB

[0306] Using a rational approach, we narrowed down the minimal number of AAVrh.10-derived amino acid residues in the 1R6 footprint that would be able to cross the BBB and confer CNS tropism. We first excluded any amino acids that were not exposed on the capsid surface, eliminating a stretch of residues located within the VP1 / 2 N-terminal region of the capsid sequence (148P, 152R, 153S, 158T, and 163K). Using the same rationale, we also excluded residues within the conserved β-strand E (343I and 347T), as well as residues within VR-II, which is the pore-forming loop connecting β-strands D and E (328Q, 330E, 332T, and 333K). By this approach, a footprint containing eight amino acids (263N, 264G, 265T, 266S, 268G (insertion relative to the AAV1 sequence), 269S, 270T, and 274T) found within VR-1 (the loop bridging β-strands B and C on AAV1R6) was selected for further evaluation ( Fig.11 A and 11B). These surface-exposed residues are located near the concave part of the 2-fold symmetry axis ( Fig.11 C and 11F), and at the base of the triple protrusion ( Fig.11 D and 11F). Stereoscopic projections of the surface-exposed residues on the 3-fold symmetry axis highlight the topological orientation of these eight residues with respect to the surrounding amino acids on the capsid surface ( Fig.11 G). As mentioned before, we also considered that these amino acids are not present in AAV1R8 / 19 / 20 variants, which are unable to transduce brain parenchyma after systemic administration.

[0307] We then designed a chimeric capsid by grafting eight amino acid residues from AAVrh.10 onto the AAV1 serotype and named this chimeric capsid AAV1RX. We injected 5 × 10 11 AAV1RX-CBh-scGFP vector was administered to 6-8 week old female C57 / Bl6 mice at a dose of 1.5 vg. GFP reporter gene expression in the brain was assessed by immunostaining 21 days after injection. Fig.11 As shown in Figure 5H, AAV1RX transduced neurons within the motor cortex and cortical neurons throughout the cortex, while demonstrating limited glial transduction and reduced vascular transduction, as previously seen using the chimeric capsids AAV1R6 and AAV1R7. Continuing this trend, numerous GFP+ pyramidal neurons were observed in the hippocampus, as well as abundant GFP+ granule cells in the dentate gyrus. Notably, GFP+ glia and endothelial cells were largely absent in these regions. In the thalamus, AAV1RX demonstrated robust neuronal transduction at levels comparable to AAV1R6 and AAV1R7, with moderate glial and endothelial cell transduction, albeit at levels higher than in other brain regions. In the hypothalamus, GFP+ neurons were sparse, and few GFP+ glia and vascular endothelial cells were observed. Finally, the preferential neuronal transduction profile displayed by AAV1RX was also seen in the striatum (particularly the caudate putamen) and amygdala ( Fig.11 H). Quantitative analysis of these brain regions and comparison with those seen for AAV1, AAVrh.10, and chimeric AAV1R6 and AAV1R7 vectors indicated that this minimal footprint of 8 amino acid residues from AAVrh.10 is critical for crossing the BBB ( Fig.13 ).

[0308] AAV1R6, AAV1R7, and AAV1RX mediate low transduction levels and biodistribution in peripheral tissues.

[0309] For comparative analysis of different chimeric capsids with parental serotypes, AAV1, AAVrh.10, AAV1R6, AAV1R7, or AAV1RX vectors packaging a single-chain luciferase reporter transgene (ssCBA-Luc) driven by the chicken β-actin promoter were used at 1 × 10 cells per animal. 11vg doses were injected into 6-8 week old female C57 / Bl6 mice via tail vein. Two weeks after injection, mice were sacrificed and tissues were harvested. Tissue lysates were subjected to luciferase activity assay and qPCR analysis to determine vector biodistribution ( Fig.12 Compared with AAV1, higher luciferase transgene expression was observed in the brain for all three chimeric vectors and a corresponding increase in viral genome copies for each chimera ( Fig.12 A and 12B). However, their transgene expression levels and viral genome copy numbers were approximately 2-3 times lower in the brain compared with AAVrh.10, which were all found to be statistically significant except for AV1RX biodistribution ( Fig.12 A and 12B). Although some variation in cardiac transduction levels was observed for AAV1RX, similar transduction levels and viral genome copy numbers in the heart were observed for AAV1R6, AAV1R7, and AAV1RX, comparable to that seen for AAV1 ( Fig.12 C and 12D). Compared with other vectors, AAVrh.10 mediated approximately 2-4 times higher cardiac luciferase expression in the heart and a corresponding approximately 2-fold higher viral genome copy number ( Fig.12 C and 12D). As demonstrated by other groups, AAVrh.10 showed several-fold higher luciferase transgene expression levels and consistently high viral genome copies in the liver. In contrast, low to background levels of luciferase expression and significantly reduced viral genome copies were detected in the liver for AAV1, 1R6, 1R7, and 1RX ( Fig.12 E and 12F). Notably, a corresponding trend in luciferase expression and viral genome copy number was detected for AAVrh.10 in the kidney ( Fig.12 G and 12H). Although the three chimeric vectors showed similar viral genome copy number levels, luciferase expression in the kidney was absent. Taken together, these data appear to indicate that chimeric AAV1R6, 1R7, and 1RX vectors are detargeted from the liver and are likely cleared from the blood circulation via the kidneys.

[0310] After intravenous administration, we identified a subset of chimeric capsids that were able to cross the BBB and effectively transduce the CNS. It was found that the ability to cross the BBB was inversely related to infectivity and sensitivity to neuraminidase in cell culture. Structural modeling and roadmap analysis further helped to identify several key residue clusters in AAVrh.10 that are able to cross the brain vasculature for transport and extensive neuronal transduction. Subsequently, we were able to further reduce the size of this footprint through a rational mutagenesis approach and then perform functional validation in vivo. In summary, we have identified the minimum footprint from AAVrh.10, which allows transport across the BBB when transplanted to other AAV strains and enables a more targeted CNS transduction spectrum compared to AAVrh. In addition, the resulting capsid is de-targeted from brain vasculature, liver, and other peripheral tissues. This new functional mapping of the footprint to the nerve provides a roadmap for engineering synthetic AAV capsids for effective CNS gene transfer with improved safety.

[0311] The parental serotypes AAV1 and AAVrh.10 used to generate the chimeric capsid library in this study are both non-human primate isolates belonging to two different clades - AAV1 belongs to clade A and AAVrh.10 belongs to clade E. Despite the evolutionary distance between them, their Cap genes share about 85% sequence homology. AAV1 is known to recognize N-linked sialic acid (Sia), and the key residues that constitute the Sia recognition footprint on the AAV1 capsid have recently been reported. The current study identified 262N, 263G, 264T, 265S, 267G, 268S, 269T, and 273T as the key residues of the chimeric AAV1RX capsid, which is derived from AAVrh.10, that are required for crossing the BBB. Although none of the Sia contact residues of AAV1 are located within the chimeric 1RX footprint, the backbone carbonyl oxygen atoms of residues S268, D271, and N272 have been implicated in stabilizing capsid-glycan interactions and increasing Sia binding affinity. Furthermore, residues at this position (D271 and N272) are located within the galactose binding footprint on AAV9. Thus, the current studies support the concept that residues within VR-I are critical.

[0312] Alignment of VP3 sequences of natural AAV isolates revealed that eight amino acid residues that confer the AAV1RX CNS phenotype are conserved in AAVrh.8 and AAVrh.39, other neurotropic capsids in clade E ( Fig.14 ). Similarly, AAV8 and AAVrh.43, also located in clade E, showed the ability to cross the BBB, albeit with much lower efficiency. Both possess 7 of the 8 residues in this footprint; therefore, introducing the complete footprint into these capsids may enhance their ability to cross the BBB.

[0313] Phenotypically, AAV1 and AAVrh.10 differ significantly in their ability to cross the BBB and transduce neurons and glia in the brain. When delivered intravenously, AAV1 exhibits preferential uptake and transduction in vascular endothelial cells. In contrast, AAVrh.10 is not only absorbed by vascular endothelial cells and transduced, but also passes through the vascular structure and transduces the following tissues, such as CNS or skeletal muscle. Current studies have identified the smallest group of residues on the AAVrh.10 capsid, which partially confer these features on the AAV1 capsid. Although this minimal footprint on the AAV1RX chimera seems to be necessary for crossing the BBB and transducing neurons, transduction in peripheral tissues (such as the liver) is significantly reduced, while cardiac expression remains similar to AAV1. These differences suggest that other domains on the AAVrh.10 capsid may play a role in conferring systemic transduction profiles. With regard to brain parenchyma, it is important to note that after entering the CNS, the transduction profile after entry of AAV1RX is preferentially that glial transduction is reduced by neurons than AAVrh.10. This may be attributed to the fact that most capsids were derived from AAV1, which is known to mediate preferential neuronal transduction after intraventricular injection. It is also possible that the unknown mechanism by which 1RX crosses the BBB mediates preferential neuronal uptake, or that other motifs / amino acid residues on the AAVrh.10 capsid may mediate post-entry steps in glial transduction.

[0314] From a clinical perspective, capsids that can cross the BBB, preferentially transduce neurons within the brain, and simultaneously de-target from the liver may demonstrate an improved safety profile for CNS-targeted gene transfer applications from systemic administration routes. Reduced vector uptake in peripheral organs, particularly the liver, may reduce the potential threat of hepatotoxicity, as demonstrated by transient elevations in transaminases in patient serum following systemic injection of certain AAV serotypes.

[0315] The AAV1R6 / 7 / X vector can be widely used for global CNS gene transfer, especially for the development of gene therapy strategies for the treatment of neurological disorders such as Friedreich's ataxia or spinal muscular atrophy.

[0316] Table 1.

[0317]

[0318]

[0319] Table 2. AAV1R7 modifications in AAV serotypes 1, 2, 3, 6, 7, 8, 9, and rh10.

[0320]

[0321] *Numbers are relative to wild type.

[0322] Table 3. Amino acid residues and abbreviations.

[0323]

[0324]

[0325] SEQ ID NO:35 (synthetically constructed adeno-associated virus capsid protein sequence): Xaa Xaa Xaa Xaa wherein Xaa at position 1 can be any naturally occurring amino acid except Ser, Xaa at position 2 can be any naturally occurring amino acid except Ala, Xaa at position 3 can be any naturally occurring amino acid except Ser, and Xaa at position 4 can be any naturally occurring amino acid except Thr.

[0326] SEQ ID NO:42 (synthetically constructed adeno-associated virus capsid protein sequence): Asn Xaa Xaa Xaa wherein Xaa at positions 2-4 may be naturally occurring amino acids.

[0327] SEQ ID NO:43 (synthetically constructed adeno-associated virus capsid protein sequence): Xaa Gly Xaa Xaa wherein Xaa at positions 1, 3, and 4 may be naturally occurring amino acids.

[0328] SEQ ID NO:44 (synthetically constructed adeno-associated virus capsid protein sequence): Xaa Xaa Thr Xaa wherein Xaa at positions 1, 2, and 4 may be naturally occurring amino acids.

[0329] SEQ ID NO: 45 (synthetically constructed adeno-associated virus capsid protein sequence): Xaa Xaa Xaa Ser wherein Xaa at positions 1, 2, and 3 may be naturally occurring amino acids.

[0330] References

[0331] The following references are incorporated herein by reference in their entirety for all purposes.

[0332] 1.Berns,K and Parrish,C(2007).Parvoviridae.Knipe DM,Howley PM,GriffinDE,Lamb RA,Martin MA,Roizman B,Straus SE(ed),Fields Virol.5th ed,vol II.,Lippincott Williams&Wilkins,Philadelphia,PA:pp 2437–2477.

[0333] 2.Gao,G,Vandenberghe,LH,Alvira,MR,Lu,Y,Calcedo,R,Zhou,X,People(2004).Clades of adeno-associated viruses are widely disseminated in humantissues.J.Virol.78:6381–8.

[0334] 3.Gao,G,Alvira,MR,Somanathan,S,Lu,Y,Vandenberghe,LH,Rux,JJ,People(2003).Adeno-associated viruses undergo substantial evolution in primatesduring natural infections.Proc.Natl.Acad.Sci.USA100:6081–6086.

[0335] 4.Agbandje-McKenna,M and Kleinschmidt,J(2011).AAV capsid structureand cell interactions.Methods Mol.Biol.807:47–92.

[0336] 5.Madigan,VJ and Asokan,A(2016).Engineering AAV receptor footprintsfor gene therapy.Curr.Opin.Virol.18:89–96.

[0337] Parvovirus Glycan Interactions.Curr.Opin.Virol.7C:108–118.

[0338] 7.Kashiwakura,Y,Tamayose,K,Iwabuchi,K,Hirai,Y,Shimada,T,Matsumoto,K,People(2005).Hepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection.J.Virol.79:609–614.

[0339] 8.Weller,ML,Amornphimoltham,P,Schmidt,M,Wilson,PA,Gutkind,JS andChiorini,JA(2010).Epidermal growth factor receptor is a co-receptor foradeno-associated virus 26serotype 6.Nat.Med.16:662–4.

[0340] Identification of PDGFR as a receptor for AAV-5 transduction.Nat.Med.9:1306–12.

[0341] Adeno-associated virus type 2contains an integrin alpha5beta1 bindingdomain essential for viral cell entry.J.Virol.80:8961–9.

[0342] An essential receptor for adeno-associated virus infection.Nature 530:108–112.

[0343] 12.Murlidharan,G,Samulski,RJ and Asokan,A(2014).Biology of adeno-associated viral vectors in the central nervous system.Front.Mol.Neurosci.7:1–9.

[0344] 13.Murlidharan,G,Crowther,A,Reardon,RA,Song,J and Asokan,A(2016).Glymphatic fluid transport controls paravascular clearance of AAV vectorsfrom the brain.JCI Insight 1:1–11.

[0345] 14.Ballabh,P,Braun,A and Nedergaard,M(2004).The blood-brain barrier:An overview:Structure,regulation,and clinical implications.Neurobiol.Dis.16:1–13.

[0346] 15.Williams,DW,Eugenin,EA,Calderon,TM and Berman,JW(2012).Monocytematuration,HIV susceptibility,and transmigration across the blood brainbarrier are critical in HIV neuropathogenesis.J.Leukoc.Biol.91:401–15.

[0347] 16.Salinas,S,Schiavo,G and Kremer,EJ(2010).A hitchhiker’s guide tothe nervous system:the complex journey of viruses andtoxins.Nat.Rev.Microbiol.8:645–655.

[0348] 17. Yang, B, Li, S, Wang, H, Guo, Y, Gessler, DJ, Cao, C, et al. (2014). Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol. Ther. 22:1299–1309.

[0349] 18. Rosenberg, JB, Sondhi, D, Rubin, DG, Monette, S, Chen, A, Cram, S, et al. (2014). Comparative Efficacy and Safety of Multiple Routes of Direct CNS Administration of Adeno-Associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human Arylsulfatase A cDNA to Nonhuman Primates. Hum. Gene Ther. Dev. doi:10.1089 / humc.2013.239[doi].

[0350] 19. Gray, SJ, Matagne, V, Bachaboina, L, Yadav, S, Ojeda, SR and Samulski, RJ(2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19:1058–1069.

[0351] 20. Zhang, H, Yang, B, Mu, X, Ahmed, SS, Su, Q, He, R, et al. (2011). Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19:1440–1448.

[0352] 21. Cearley, CN, Vandenberghe, LH, Parente, MK, Carnish, ER, Wilson, JM and Wolfe, JH (2008). Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther. 16:1710–8.

[0353] 22. Grieger, JC, Snowdy, S and Samulski, RJ (2006). Separate Basic Region Motifs within the Adeno-Associated Virus Capsid Proteins Are Essential for Infectivity and Assembly. J. Virol. 80:5199–5210.

[0354] 23. Sonntag, F, Bleker, S, Leuchs, B, Fischer, R and Kleinschmidt, JA (2006). Adeno-associated virus type 2 capsids with externalized VP1 / VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J. Virol. 80:11040–11054.

[0355] 24. Bowles, DE, McPhee, SW, Li, C, Gray, SJ, Samulski, JJ, Camp, AS, et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20:443–455.

[0356] 25. Li, C, Diprimio, N, Bowles, DE, Hirsch, ML, Monahan, PE, Asokan, A, et al. (2012). Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J. Virol. 86:7752–7759.

[0357] 26. Bleker, S, Sonntag, F and Kleinschmidt, JA (2005). Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 79:2528–2540.

[0358] 27. Wu, Z, Miller, E, Agbandje-McKenna, M and Samulski, RJ (2006). Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80:9093–103.

[0359] 28. Huang, L-Y, Patel, A, Ng, R, Miller, E B, Halder, S, Mckenna, R, et al. Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Sites. doi:10.1128 / JVI.00161-16.

[0360] 29. Bell, C L, Gurda, B L, Vliet, K Van, Agbandje-McKenna, M and Wilson, J M (2012). Identification of the galactose binding domain of the AAV9 capsid. J. Virol. 86:7326–7333.

[0361] 30. Rosenberg, J B, Sondhi, D, Rubin, D G, Monette, S, Chen, A, Cram, S, et al. (2014). Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates. Hum. Gene Ther. Clin. Dev. 25:164–77.

[0362] 31. Cearley, C N and Wolfe, J H (2006). Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 13:528–37.

[0363] 32. Hadaczek, P, Forsayeth, J, Mirek, H, Munson, K, Bringas, J, Pivirotto, P, et al. (2009). Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum. Gene Ther. 20:225–237.

[0364] 33. Chen, S, Kapturczak, M, Loiler, SA, Zolotukhin, S, Glushakova, OY, Madsen, KM, et al.

[0365] (2005). Efficient Transduction of Vascular Endothelial Cells with Recombinant Adeno-Associated Virus Serotype 1 and 5 Vectors. Hum. Gene Ther. 16:235–247.

[0366] 34. Pulicherla, N, Shen, S, Yadav, S, Debbink, K, Govindasamy, L, Agbandje-McKenna, M, et al. (2011). Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene Transfer. Mol. Ther. 19:1070–1078.

[0367] 35. Asokan, A, Conway, JC, Phillips, JL, Li, C, Hegge, J, Sinnott, R, et al. (2010). Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 28:79–82.

[0368] 36. Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., et al. (2014). Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371: 1994–2004.

[0369] 37. Mingozzi, F and High, K. A. (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122: 23–36.

[0370] 38. Kumar, S, Stecher, G and Tamura, K. (2016). MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol. Biol. Evol. 33: 1870–4.

[0371] 39. Saitou, N and Nei, M. (1987). The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4: 406–25.

[0372] 40. Felsenstein, J. (1985). CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP. Evolution (NY). 39: 783–791.

[0373] 41.Murlidharan,G,Sakamoto,K,Rao,L,Corriher,T,Wang,D,Gao,G,People(2016).CNS-restricted Transduction and CRISPR / Cas9-mediated Gene Deletion with anEngineered AAV Vector.Mol.Ther.-Nucleic Acids 5:e338.

[0374] Genome-wide atlas of gene expression in the adult mouse brain.Nature445:168–176.

[0375] Production,purification and preliminary X-raycrystallographic studies of adeno-associated virus serotype 1.ActaCrystallogr.Sect.F Struct.Biol.Cryst.Commun.62:1271–1274.

[0376] 44.Bordoli,L,Kiefer,F,Arnold,K,Benkert,P,Battey,J and Schwede,T(2008).Protein structure homology modeling using SWISS-MODELworkspace.Nat.Protoc.

[0377] 45. Nam, HJ, Lane, MD, Padron, E, Gurda, B, McKenna, R, Kohlbrenner, E, et al. (2007). Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81: 12260–12271.

[0378] 46. Krissinel, E and Henrick, K (2004). Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. Sect. D Biol. Crystallogr. 60: 2256–2268.

[0379] 47. Emsley, P, Lohkamp, B, Scott, WG and Cowtan, K (2010). Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66: 486–501.

[0380] 48. Carrillo-Tripp, M, Shepherd, CM, Borelli, IA, Venkataraman, S, Lander, G, Natarajan, P, et al. (2009). VIPERdb2: an enhanced and web API enabled relational database for structural virology. Nucleic Acids Res. 37: D436-42.

[0381] 49. Xiao, C and Rossmann, MG (2007). Interpretation of electron density with stereographic roadmap projections. J. Struct. Biol. 158: 182–187.

Claims

1. An adeno-associated virus (AAV) capsid protein, wherein the AAV capsid protein comprises the amino acid sequence of SEQ ID NO: 30 (AAV1RX').

2. An AAV capsid comprising the capsid protein of claim 1.

3. A polynucleotide encoding the AAV capsid protein of claim 1. An expression vector comprising the polynucleotide according to claim 3. A cell comprising the polynucleotide of claim 3 or the expression vector of claim 4.

6. A viral vector comprising: (a) the AAV capsid of claim 2; and (b) a nucleic acid comprising at least one terminal repeat sequence, wherein the nucleic acid is encapsidated by an AAV capsid.

7. A composition comprising the viral vector of claim 6 in a pharmaceutically acceptable carrier.

8. Use of the viral vector of claim 6 in the manufacture of a medicament for introducing a nucleic acid molecule into a cell, comprising contacting the cell with a medicament comprising the viral vector of claim 6.

9. Use of the viral vector of claim 6 in the manufacture of a medicament for delivering a nucleic acid molecule to a subject, comprising administering to the subject a medicament comprising the viral vector of claim 6.

10. The use of claim 9, wherein the viral vector and / or composition is administered to the central nervous system of the subject.

11. The use of claim 10, wherein the viral vector and / or composition is delivered across the blood-brain barrier.

12. The use of any one of claims 9-11, wherein the subject is a human.

13. The use of claim 12, wherein the viral vector comprises a nucleic acid molecule of interest.

14. The use according to claim 13, wherein the nucleic acid molecule of interest encodes a therapeutic protein or a therapeutic RNA.

15. Use of the viral vector according to claim 6 in the manufacture of a medicament for selectively delivering a nucleic acid molecule of interest to neuronal cells, comprising contacting neuronal cells with a medicament comprising the viral vector according to claim 6, wherein the viral vector comprises the nucleic acid molecule of interest.

16. The use according to claim 15, wherein the delivering comprises selectively delivering the nucleic acid molecule of interest to cardiomyocytes.

17. The use according to claim 16, wherein the nucleic acid molecule of interest encodes a therapeutic protein or a therapeutic RNA.

18. The use according to claim 16, wherein the neuronal cells and / or cardiomyocytes are in a subject.

19. The use according to claim 18, wherein the viral vector is targeted from spleen cells, hepatocytes or kidney cells.

20. The use according to claim 18, wherein the subject is a human subject.

21. Use of the viral vector according to claim 6 in the manufacture of a medicament for treating a neurological disorder or defect in a subject, the treatment comprising administering to the subject a medicament comprising the viral vector according to claim 6, wherein the viral vector comprises a nucleic acid molecule encoding a therapeutic protein or therapeutic RNA effective in treating the neurological disorder or defect.

22. Use of the viral vector according to claim 6 in the manufacture of a medicament for treating a subject's neurological and cardiovascular disorders or defects, the treatment comprising administering to the subject a medicament comprising the viral vector according to claim 6, wherein the viral vector comprises a nucleic acid molecule encoding a therapeutic protein or therapeutic RNA effective in treating the neurological and cardiovascular disorders or defects.

23. The use according to any one of claims 9-11 or 18-22, wherein the medicament is administered to the subject by intravenous, intraarterial or intraperitoneal route.

24. The use according to any one of claims 9-11 or 18-22, wherein the medicament is administered to the subject via an intraventricular, intracisternal, intraparenchymal, intracranial and / or intrathecal route.